Reference Notes for Palliative Care Consultation
Robert F Johnson MD, MEd
The interprofessional health care specialty of palliative care employs holistic evaluation and
person-centered communication in the care of people with life-threatening illness. Palliative
care clinicians are consulted for one or more of the following reasons:
-

Symptom assessment and management
Assistance with making difficult decisions about continued use or withdrawal of lifesustaining interventions
Communication for planning the most appropriate care setting to meet
person/family goals for end-of-life care
Assessment of suitability and eligibility for hospice care

This resource is a compilation of previously published documents and tools useful to palliative
care clinicians in preparing for and conduction these consultations. In addition, it can be a
reference for students and clinical trainees doing course work, analyzing case studies, or
simulating clinical communication scenarios. The materials are indexed for easy retrieval,
referenced to acknowledge sources and allow further exploration, and organized into the
following categories:
-

Palliative Care Definitions/Domains/Dimensions
Communication
Symptom Assessment
Functional Status Evaluation
Prognostication
End-of-Life Assessment and Management
Symptom Management
Hospice Eligibility Criteria
Withholding and Withdrawing Life-Sustaining Interventions
Pediatric End-of-Life Issues
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DNAR = Do-Not-Attempt-Resuscitation
DVT = Deep Vein Thrombosis
ECOG = Eastern Cooperative Oncology Group
EF = ejection fraction, cardiac
EOL = End-of-Life
ESRD = End-stage Renal Disease
FAST = Functional Assessment STaging (dementia)
FEV1 = Forced Expiratory Volume 1 Second
GCS = Glasgow Coma Scale
Greater Than (>), Less Than (<)
HD = hemodialysis
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HIV = Human Immunodeficiency Virus
IABP = Intra-Aortic Balloon Pump
IADL = Instrumental Activities Daily Living
KPS = Karnosky Performance Scale
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LDH = Lactic DeHydrogenase level
LVAD = Left Ventricular Assist Device
MBO = Malignant Bowel Obstruction
MRIS = Mortality Risk Index Score
m-R = modified Rankin score
MAC = mycobacterium avium complex
NCF = National Consensus Project for Quality Palliative Care
NIPPV = Non-Invasive Positive Pressure Ventilation
NHL = Non-Hodgkins Lymphoma
NQF = National Quality Forum
NSAID = Non-steroidal anti-inflammatory drug
NSCLC = Non-Small Cell Lung Cancer
NYHA = New York Heart Association
PAD = Pain/Agitation/Delerium
PaP = Palliative Prognostic Score
PC = Palliative Care
PACD = Palliative Care for Advanced Disease
PCN = Palliative Care Notes
PE = Pulmonary Embolism
PIMOA = Prognostic Index 1-yr Mortality Older Adults
plt = platelet level
PPI = Palliative Prognostic Index
PPS = Palliative Performance Scale
QOL = Quality of Life
QTc = corrected QT interval on ECG
RASS = Richmond Agitation-Sedation Scale
SAS = Sedation-Agitation Scale (Riker)

SBP = Spontaneous Bacterial Peritonitis
SDM = Shared Decision-Making
SCCM = Society of Critical Care Medicine
SCLC = Small Cell Lung Cancer
SNRI = Serotonin Norepinephrine Re-Uptake Inhibitor
SQ = subcutaneous
SSRI = Selective Serotonin Re-Uptake Inhibitor
TCA = Tri-Cyclic Anti-Depressant
UDT = urine drug/toxin screen
WBC = White Blood Cell count
WWLST = Withholding/Withdrawing Life-Sustaining Treatment

WHO Definition of Palliative Care
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Palliative care is an approach that improves the quality of life of patients and their families facing the problem
associated with life-threatening illness, through the prevention and relief of suffering by means of early
identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and
spiritual. Palliative care:
• provides relief from pain and other distressing symptoms;
•

affirms life and regards dying as a normal process;

•

intends neither to hasten or postpone death;

•

integrates the psychological and spiritual aspects of patient care;

•

offers a support system to help patients live as actively as possible until death;

•

offers a support system to help the family cope during the patients illness and in their own bereavement;

•

uses a team approach to address the needs of patients and their families, including bereavement
counselling, if indicated;

•

will enhance quality of life, and may also positively influence the course of illness;

•

is applicable early in the course of illness, in conjunction with other therapies that are intended to
prolong life, such as chemotherapy or radiation therapy, and includes those investigations needed to
better understand and manage distressing clinical complications.

WHO Definition of Palliative Care for Children
Palliative care for children represents a special, albeit closely related field to adult palliative care. WHO’s
definition of palliative care appropriate for children and their families is as follows; the principles apply to other
pediatric chronic disorders (WHO; 1998a):
• Palliative care for children is the active total care of the child's body, mind and spirit, and also involves
giving support to the family.
•

It begins when illness is diagnosed, and continues regardless of whether or not a child receives
treatment directed at the disease.

•

Health providers must evaluate and alleviate a child's physical, psychological, and social distress.

•

Effective palliative care requires a broad multidisciplinary approach that includes the family and makes
use of available community resources; it can be successfully implemented even if resources are limited.

•

It can be provided in tertiary care facilities, in community health centers and even in children's homes.

Definition of palliative care (English):

European Association for Palliative care

Palliative care is the active, total care of the patients whose disease is not responsive to curative treatment. Control of
pain, of other symptoms, and of social, psychological and spiritual problems is paramount.
Palliative care is interdisciplinary in its approach and encompasses the patient, the family and the community in its
scope. In a sense, palliative care is to offer the most basic concept of care – that of providing for the needs of the
patient wherever he or she is cared for, either at home or in the hospital.
Palliative care affirms life and regards dying as a normal process; it neither hastens nor postpones death. It sets out
to preserve the best possible quality of life until death.

Definition of Hospice and Palliative Medicine – AAHPM
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Palliative care focuses on improving a patient’s quality of life by managing pain and other distressing symptoms of a
serious illness. Palliative care should be provided along with other medical treatments. Hospice is palliative care for
patients in their last year of life. Hospice care can be provided in patients’ homes, hospice centers, hospitals, longterm care facilities, or wherever a patient resides. Physicians who specialize in hospice and palliative medicine work
with other doctors and healthcare professionals; listen to patients and align their treatments with what’s important to
them; and help families navigate the complex healthcare system.

EPEC Dimensions of Whole Patient Assessment
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Nine Dimensions of Whole Patient Assessment for Palliative Care
1. Illness, Treatment – Summary
2. Physical
3. Psychological
4. Decision-Making
5. Communication
6. Social
7. Spiritual
8. Practical
9. Anticipatory Planning
Perspectives on a Suffering Person
1.
2.
3.
4.

Disease – what a person has
Dimension – what a person is
Behavior – what a person does
Life Status – what a person wants

National Consensus Project for Quality Palliative Care (NCF) – National Quality Forum (NQF) Domains:
1. Structure/Process
2. Physical
3. Psychologic/Psychiatric
4. Social
5. Spiritual/Existential/Religious
6. Cultural
7. Care of Imminently Dying
8. Ethical/Legal
NCF: Palliative care means patient- and family-centered care that optimizes QOL by anticipating,
preventing, and treating suffering. Palliative care throughout the continuum of illness involves
addressing physical, emotional, emotional, social, and spiritual needs – and to facilitate patient
autonomy, access to information, and choice.

Palliative Care for Advanced Disease (PCAD)
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PCAD Introduction

Purpose of PCAD:
The Goals of PCAD are to:
Respect patient autonomy, values, and decisions
Continually clarify the goals of care
Minimize symptom distress at the end of life
Optimize appropriate supportive interventions and consultations
Reduce unnecessary interventions
Support families by coordinating services
Eliminate unnecessary regulations
Provide bereavement services for families and staff
Facilitate the transition to alternative care settings, such as hospice, when appropriate

PCAD consists of three components (forms are available in .pdf format):
PCAD Care Path – the interdisciplinary plan of care
PCAD Daily Patient Care Flowsheet – an interdisciplinary documentation tool for daily
assessments and interventions
PCAD Healthcare Provider/MD-Order Sheet – a documentation tool and suggestions for
symptom control approaches

Process for utilization of PCAD Pathway (See Flowchart below):
Step 1: Patient Identification
Identification of a patient that is likely to die during this hospitalization (i.e., likely to die within
minutes to days) by any staff member. Any staff member or others listed may suggest a patient
for PCAD.
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Step 2: Interdisciplinary Assessment
Interdisciplinary assessment of the patient for PCAD and
discussion with the primary healthcare provider – The unit
leadership assesses the appropriateness of the patient for PCAD
and initiates an order for PCAD with the primary healthcare
provider.
Step 3: Provider Clarification
Clarification of goals of care with the patient/family by the primary
healthcare provider – The primary healthcare provider clarifies the
goals of care with the patient and/or family and orders PCAD if
end-of-life supportive care is the primary goal of care.
Step 4: Implementation
The primary healthcare provider orders PCAD using the PCAD
Provider Order Sheet and rewrites the orders for the patient.
Nurses complete the demographic information on the PCAD
Pathway and initiate a PCAD Daily Patient Care Flowsheet.
Step 5: Discharge
The patient is discharged to an alternative care setting or dies on
unit. A family bereavement policy is initiated (e.g., condolence
card and educational materials sent) and a staff debriefing session
is conducted.
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Brief Consultation Outline
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Name/Service, Attending, Patient Name/#, Requesting/Reason/Date
Palliative Care Assessment:
Introduction: Age, Gender, Location, Adm Date, 1˚ Disease, CC
Background: Social (Family, Work, Live)
Psych (prior dx, coping, substances)
Spirit (religion, existential)
PMH:
Med, Surg, Allergies, incoming Meds
1˚Disease:
Dx, Rx, current Status, Adv Directive, Code Status
Symptoms: Describe, Assess
Pain
Fatigue
Sedation, Drowsiness
Sleep Disturbance
Appetite, Dysphagia, Wt Loss
N/V, Constipation, Diarrhea
Incontinence
Itch
Depression, Anxiety
Hallucination, Myoclonus, Seizure
Exam:
VS
Cachexia, Wt Loss, Overt Manifestation of 1˚ Disease
Cognition/Delerium
Mouth, Nodes, Chest, Heart, Abd, Skin, Extremities, Neuro
Describe Painful Locations
Other Info:
Relevant Labs, Imaging, Consults
Impressions: Palliative Care Diagnoses
Assessment: Analysis of sx and/or perspective on communication/decision- making
Recommend/Plan
Assessment in Palliative Medicine – Outline
Patient

Who is patient? – social context
What is wrong? – illness, where in course of illness
Is patient “clear-headed” – What does patient understand?
What are Goals of Care?
Prolong survival
Optimize function
Optimized comfort
What are consequences – How are you coping?

Physical/psychological/social/existential
What are deeper thoughts/future problems
Family

HCP
Care Plan

Who is family? – social context
What is physical/psychological well-being of family?
Coping?
What are deeper thoughts/future problems/other losses in past?
Who is involved?
? expertise/experience/understanding of illness
Medical condition/Goals of care
Patient/family issues
Physical
Psychological
Spiritual/existential
Social
Communication/decision-making
Understanding
HCP issues
Staffing
Training
Resources
Emotional coping
Coping assessment
Patient
Family
HCP
Contingency planning
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Patient-Centered Communication (PCC):
Elements:

Goal is Shared Decision-Making (SDM)
Issues/Discussion Points

Strategies

Setting
Assess P/F Perspective
(P/F=Patient/Family)

Environment/Introductions
(Start Here)
Condition
Implication
Values/Goals/Preferences
Information/Decision Style

“Warning Shot”

Exchange Information

Diagnosis
Prognosis
Bad News
Options
Curative
Palliative
Hospice
EOL/LSI/DNAR

Active listening
“Tell-Me-More”
“Most Important”
3 Levels
Correlate to V/G/P
“Ask-Tell-Ask”

Respond to Emotion
Manage Uncertainty

“NURSE”
Acknowledge
Hope-Address/Reframe
Nonabandonment
(Finish Here)
Information
Goals/Preferences
Decision(s)
Plan(s)
Follow-up

Summary/Recap

Shared Decision-Making:

Overall Purpose:

“VALUE”
V alue Patient/family statements
A cknowledge emotion/uncertainty
L isten
U nderstand
E licit questions

“Best-Worst”
“Hope-Worry”

Mutual/shared Understanding
Mutual/shared Goals and Plan
Healing Relationship

“ASCEND”

A nticipate (pre-planning)
S ummarize (understanding)
C oncerns (acknowledge)
E xplore, Explain (information, goals)
N ext steps
D ocument
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SPIKES:

“Bad News” format (and a “roadmap” for PCC communication event)

S:

Setting

“Set-up”: Preparation/Planning
Environment/Comfort
Avoid Distractions
Participants/Introductions
“Warning Shot”

P:

Patient/Family
Perspective

? Perception of current status
? Expectations
? Misunderstanding/Misconception/Denial
Values/Goals

I:

Invitation

K:

Knowledge

E:

Emotion/Uncertainty

S:

Summary

Type/Extent of Information (Prognosis)
Gauge to individual
Direct/Avoid Jargon
Small “Chunks”
Ask-Tell-Ask
Relate information to values/goals
Address decision points
Overall goals
Necessary specifics (eg DNR)
Respond to Emotion
(NURSE mnemonic)
Manage Uncertainty
Summarize
Assess Understanding
Strategy/Next Steps
Follow-up
Nonabandonment

______________________________________________________________________________
NURSE: Responding to Emotion

N:

Name

Suggestive rather than Declarative
(“it sounds like…..”)
Active Listening
Restate/Summarize

U:

Understand

Exploration/Active Listening/Appropriate Silence
(“I’m understanding you to say……”)
(“I cannot imagine what it is like….”)
Avoid Premature Reassurance

R:

Respect

Acknowledge/Respect Intensity of Emotion
Normalize
Praise Coping Skills
Non-Verbal Cues Important

S:

Support

Expression of Concern
Articulate Understanding
Willingness to Help/Partner
Nonabandonment

E:

Explore

(“tell me more….”)
Empathy (contrasted with sympathy)
(“I…..you….”)

19

UFO-UFO
Understand: elicit patient’s understanding of their medical situation
Listen for gaps in knowledge, mixed messages
Choose your words to match theirs
Listen for concrete vs abstract thinking styles
“I’m wondering if you could tell me what you already know about your illness”
What have the doctors told you about your father’s condition?”
Fill in Gaps: add your understanding of the situation
May need to break bad news
Take time to support emotions
“Let me fill in some details”
I have some new information…….”
Outcomes: elicit the range of patients desired outcomes; explore values, hopes, fears, expectations
Have patient describe an acceptable quality of life and function
Test the lower limit carefully
“Paint me a picture of what you would be able to do and enjoy”
“If things were a bit worse such as ______ would that be acceptable?”
“Are there health situations you are worried about getting stuck in?”
“Is there a quality of life your mother would find intolerable?”
Given everything that has gone on, how do you think this will most likely turn out?”

Understand: find out more about the patient as a person and why they want what they want
“Help me understand your decision-making”
“Can you tell me about yourself that will help me understand you and where you’re coming from”
“What things are most important to you right now”
“Has your father or anyone in his family ever had experiences with severe illness – did he make any comments
about his wishes then?”
Feasible Outcome: describe the range of outcomes you think are possible with treatment
May need to break bad news
Take time to support emotions
“Here is what we think are the possible results/outcomes of treatment – the best case scenario is ________,
unfortunately there is a real possibility that _______ might happen, at this point what I think is
most likely to happen is ________”

If there is overlap between the lowest acceptable QOL and the feasible outcomes:
“Since you are telling me you (your ___) would be OK even if the best we could do is get you out of the hospital to a nursing
home, I recommend we try the _______, here is the plan I would recommend……….., what do you think? OR Am I understanding you
correctly?”
If there is NO overlap between the lowest acceptable QOL and feasible outcomes:
“We think the best we can hope for with the most aggressive continued treatment is to get your ______ out of the hospital but
would still need 24 hour care in a nursing home, probably for the rest of _____ life, but ___has said this would not be acceptable.
In that case, I’m sorry to say that I cannot recommend that we continue the current level of treatment. We will not be able to get
_____ to a life _____ would accept. I recommend that we focus on things we can accomplish, like ensuring the absence of pain
and other symptoms”
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Communication – Seven Steps:
Prepare
Establish
Determine
Deliver
Respond
Establish

(patient perspective)
(patient/family preferences)
(information)
(emotion)
(plan, goals)

_________________________________________________________________________________

Decision-Making Communication Tool

Medical Indications

Patient Preferences

Diagnosis
Prognosis
Intervention
Risks
Benefits
Symptom Management
Nutrition

Quality of Life
Activities
Relationships
Emotional
Spiritual

Informed/involved in decisions
Plan of care
Expectations
Resuscitation

Contextual Issues
Home
Caregiver/Family
Cultural
Spiritual
Financial
Legal
Social

“how much information do you want to know about your prognosis”?
Wants to know:
determine specific information wanted
how to present:
provide information with “ballpark” exception
“it is impossible to predict for any individual
with certainty but the average person with
your………..”
Does not want to know: assess why, acknowledge emotion, provide enough for decisions or
establish proxy
Ambivalent or afraid:

acknowledge, explore concerns, provide options for presenting
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Pain Assessment – Comprehensive

Patient’s self-report is the “gold” standard, alternative methods/observations if patient unable to report
Pain Experience and Context
Location, referral, radiation
Intensity
Last 24 hours and current, rest/movement
Interference with activities
General, mood, relationships, sleep, appetite
Timing
Onset, duration course; persistent/intermittent
Quality
Aching, stabbing throbbing, pressure (somatic)
Gnawing, cramping, aching, sharp
(visceral)
Sharp, tingling, shooting
(neuropathic)
Aggravating/Alleviating factors
Other symptoms
Current pain management
Meds, how much/often, prescriber
Response, relief, compliance, side effects
Prior pain therapies
Reason, length of use, response,?discontinued
Special issues
Meaning/consequence for patient/family
Knowledge/beliefs regarding pain medications
Cultural, religious, spiritual, existential beliefs
Goals and expectations
Psychosocial/psychiatric
Prior/current substance abuse
Risk factors for aberrant use/diversion (environmental, social)
Risk factors for undertreatment
Peds, geriatric, minorities, female
History abuse, history neuropathic pain
Cultural factors
Medical history – current/prior
Oncologic treatment, chemotherapy, radiation, surgery
Other significant illnesses. Pre-existing chronic pain
Physical exam, labs, imaging
>> Pain diagnosis and individualized pain treatment plan based on mutually developed goals
Pain diagnosis includes etiology (disease process, treatment implication) and pathophysiology
(somatic/visceral, neuropathic)
Pain Assessment Mnemonic:
W ords
I ntensity
L ocation
D uration
A ggravating/Alleviating

4 A’s of pain management outcome
A nalgesia
A ctivities
A dverse effects
A berrant behavior

Pain Assessment Observations in Cognitively Impaired
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Facial Expression

frown, fright, grimace
forehead wrinkle, rapid blinking

Vocalizations

sigh, moan, groan, grunt, chant, call out
noisy breathing, ask for help, verbally abusive

Body Movements

rigid, tense, guarded, fidget, pace, rock
restricted movement; altered gait, mobility

Change in Interpersonal
Interaction

aggressive, combative, decreased interaction
inappropriate, disruptive, withdrawn

Change in Activity Pattern
or Routines

refuse food, appetite change, increased resting, change in sleep pattern
stop routines, wandering

Mental Status Changes

crying/tears, confusion, irritable, distressed
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Pain Assessment in Critically Ill, Sedated, on Mechanical Ventilation
Categories:

FACIAL EXPRESSION

UPPER LIMBS

COMPLIANCE WITH
VENTILATOR

(POINTS)
(1)
relaxed

no movement

tolerating

(2)
partially tightened brow

partially bent

coughing but tolerating
most of time

(3)
fully tightened brow

fully bent, finger flexion

fighting ventilator

(4)
grimacing

retracted

Score points for each category
Total 5 or greater consistent with pain response

unable to control ventilation
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Memorial Pain Assessment Card
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Pain Assessment in Advanced Dementia Scale (PAINAD)
Instructions: Observe the patient for five minutes before scoring his or her behaviors. Score the
behaviors according
to the following chart. Definitions of each item are provided on the following page. The patient can be
observed under
different conditions (e.g., at rest, during a pleasant activity, during caregiving, after the administration of
pain
medication).

Behavior
Score
1. Breathing Independent of vocalization
0
Normal
1
Occasional labored breathing, short periods of hyperventilation
2
Noisy labored breathing, long periods of hyperventilation, Cheyne-Stokes
2. Negative vocalization
0
none
1
occasional moan or groan, low-level speech with a major disapproving quality
2
repeated trouble calling out, loud moaning or groaning, crying
3. Facial expression
0
smiling or inexpressive
1
sad, frightened, frown
2
facial grimacing
4. Body language
0
relaxed
1
tense, distressed pacing, fidgeting
2
rigid, fists clenched, knees pulled up or pushing away, striking out
5. Consolability
0
no need to console
1
distracted or reassured by voice or touch
2
unable to console, distract, or reassure

TOTAL SCORE
(Warden et al., 2003)

Scoring:
The total score ranges from 0-10 points. A possible interpretation of the scores is: 1-3=mild pain; 46=moderate pain; 7-10=severe pain. These ranges are based on a standard 0-10 scale of pain, but have
not been substantiated in the literature for this tool.
Source:
Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in
Advanced
Dementia (PAINAD) scale. J Am Med Dir Assoc. 2003;4(1):9-15.
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PAINAD Item Definitions
(Warden et al., 2003)

Breathing
1. Normal breathing is characterized by effortless, quiet, rhythmic (smooth) respirations.
2. Occasional labored breathing is characterized by episodic bursts of harsh, difficult, or wearing
respirations.
3. Short period of hyperventilation is characterized by intervals of rapid, deep breaths lasting a short
period of time.
4. Noisy labored breathing is characterized by negative-sounding respirations on inspiration or expiration.
They may
be loud, gurgling, wheezing. They appear strenuous or wearing.
5. Long period of hyperventilation is characterized by an excessive rate and depth of respirations lasting a
considerable time.
6. Cheyne-Stokes respirations are characterized by rhythmic waxing and waning of breathing from very
deep to
shallow respirations with periods of apnea (cessation of breathing).
Negative Vocalization
1. None is characterized by speech or vocalization that has a neutral or pleasant quality.
2. Occasional moan or groan is characterized by mournful or murmuring sounds, wails, or laments.
Groaning is
characterized by louder than usual inarticulate involuntary sounds, often abruptly beginning and ending.
3. Low level speech with a negative or disapproving quality is characterized by muttering, mumbling,
whining,
grumbling, or swearing in a low volume with a complaining, sarcastic, or caustic tone.
4. Repeated troubled calling out is characterized by phrases or words being used over and over in a tone
that
suggests anxiety, uneasiness, or distress.
5. Loud moaning or groaning is characterized by mournful or murmuring sounds, wails, or laments in
much louder
than usual volume. Loud groaning is characterized by louder than usual inarticulate involuntary sounds,
often abruptly
beginning and ending.
6. Crying is characterized by an utterance of emotion accompanied by tears. There may be sobbing or
quiet weeping.
Facial Expression
1. Smiling or inexpressive. Smiling is characterized by upturned corners of the mouth, brightening of the
eyes, and a
look of pleasure or contentment. Inexpressive refers to a neutral, at ease, relaxed, or blank look.
2. Sad is characterized by an unhappy, lonesome, sorrowful, or dejected look. There may be tears in the
eyes.
3. Frightened is characterized by a look of fear, alarm, or heightened anxiety. Eyes appear wide open.
4. Frown is characterized by a downward turn of the corners of the mouth. Increased facial wrinkling in
the forehead
and around the mouth may appear.
5. Facial grimacing is characterized by a distorted, distressed look. The brow is more wrinkled, as is the
area around
the mouth. Eyes may be squeezed shut.
Body Language
1. Relaxed is characterized by a calm, restful, mellow appearance. The person seems to be taking it
easy.
2. Tense is characterized by a strained, apprehensive, or worried appearance. The jaw may be clenched.
(Exclude
any contractures.)
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3. Distressed pacing is characterized by activity that seems unsettled. There may be a fearful, worried, or
disturbed
element present. The rate may be faster or slower.
4. Fidgeting is characterized by restless movement. Squirming about or wiggling in the chair may occur.
The person
might be hitching a chair across the room. Repetitive touching, tugging, or rubbing body parts can also be
observed.
5. Rigid is characterized by stiffening of the body. The arms and/or legs are tight and inflexible. The trunk
may appear
straight and unyielding. (Exclude any contractures.)
6. Fists clenched is characterized by tightly closed hands. They may be opened and closed repeatedly or
held tightly
shut.
7. Knees pulled up is characterized by flexing the legs and drawing the knees up toward the chest. An
overall troubled
appearance. (Exclude any contractures.)
8. Pulling or pushing away is characterized by resistiveness upon approach or to care. The person is
trying to escape
by yanking or wrenching him- or herself free or shoving you away.
9. Striking out is characterized by hitting, kicking, grabbing, punching, biting, or other form of personal
assault.
Consolability
1. No need to console is characterized by a sense of well-being. The person appears content.
2. Distracted or reassured by voice or touch is characterized by a disruption in the behavior when the
person is
spoken to or touched. The behavior stops during the period of interaction, with no indication that the
person is at all
distressed.
3. Unable to console, distract, or reassure is characterized by the inability to soothe the person or stop a
behavior with
words or actions. No amount of comforting, verbal or physical, will alleviate the behavior.

PCN Pain Assessment in Patients with Active Cancer
Characterize multiple dimensions of pain:
Intensity
Temporal features (onset, course, daily fluctuation, breakthrough)
Location, radiation
Quality
Aggravating/alleviating factors
Understand nature of pain:
Cause
Pathophysiology
Pain syndrome
Identify effects of the Pain on Quality of Life:
Physical function and well-being
Mood, coping, psychological well-being
Social and family relationships
Sleep, vitality, sexuality
Clarify extent of malignant disease, planned intervention(s), prognosis
Clarify nature and quality of previous testing and past treatments
Detail medical comorbidities
Elucidate psychiatric comorbidities:
Substance-use history
Depression/anxiety
Personality disorder
Detail current interventions/medications
Identify other need for palliative care intervention:
Other symptoms
Psychosocial/spiritual distress
Caregiver burden
Communication, care coordination, goal-setting
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PCN Psychological Assessment - Ten Essential Questions
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1. Have you been feeling down much of the day for the past few weeks?
2. Do you find that you don’t experience pleasure or enjoyment from your usual activities, not
because of pain, but because you just don’t feel interested?
(depression)
3. During the last six months have you been nervous or worried a lot of the time about bad things
that might happen?
4. Has worry at night – or during the day – kept you from being able to sleep soundly?
(anxiety)
5. Have you experienced a past or recent loss with which you are still having some difficulty
coping?
(bereavement)
6. Are you currently worried about your family members’ ability to cope with your illness?
(relationships)
7. Have you found that you are struggling to find a sense of purpose in your life or to feel more
hopeful?
8. Have you been struggling with your faith as a result of your illness?
(existential, spiritual)
9. What is most stressful to you about your illness? (e.g. change in function or appearance, fear of
dying)
10. Circle the number below that best describes in general how much distress you have been
experiencing in the past week including today:
No Distress__1__2__3__4__5__6__7__8__9__10 Extremely Distressed
(6+ on scale or 5+ “yes” answers > consider psych referral)

Psychosocial Distress Mnemonic
B ackground (what is going on?)
A ffect
(how feel?)
T rouble
(what bothers?)
H andle
(how cope?)
E mpathy
Depression screen:

Have you been bothered by feeling down, depressed, or hopeless?
Have you been bothered by a lack of pleasure in doing things?

PCN Psychologic Distress – Common Areas/clinician response

Fear of Burdening Family:
Ask for more information, clarify meaning
Identify communication barriers
Normalize feelings
Open communication
“disease is a burden, not you”
Consider family support a gift
Fear of Dying/Leaving Family:
Stay present emotionally
Normalize (vs. “naturalize”)
Reassure regarding symptom control
Determine what has been done to prepare for death
Identify communication barriers
Acknowledge difficulty of communication
Listen more than speak
Acknowledge courage to speak of this issue
Denial vs Approach:
Listen, ask reflective questions
Clarify “accept” and “acknowledge”
Assess impact on family
Assess communication with family
Do not be a prognosis “hammer”
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PCN Anticipatory Grief, MDD, PTSD
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Anticipatory Grief
Anticipated loss of one’s self, prepare for separation from world
Progression of changes (emotional, social, spiritual, physical, cognitive, behavioral) through which a
person attempts to recognize and resolve or adjust to loss of his/her own place
Withdrawal from family, friends
Sadness, crying
Anxiety
Ruminations about past
MDD = Major Depressive Disorder
2 weeks of depressed mood or loss of interest (anhedonia) + at least four symptoms:
Sleep disturbance – insomnia or hypersomnia
Guilt, worthlessness
Lack of energy
Loss of concentration, difficulty making decisions
Anorexia and/or weight loss
Psychomotor agitation or retardation
Suicidal ideation
-symptoms are either new or worse than before the depressive episode, and they persist for
most of the day, nearly every day, for 2 consecutive weeks
-episode is accompanied by clinically significant distress or impairment in social, occupational, or
other important areas of functioning
-symptoms are NOT due to bereavement or to physiological effect of medication, general
medical condition, or substance abuse
-mood described as “depressed”, “sad”, “hopeless”, “doen in the dumps”
Dysthymia = depressed mood + hopelessness (not suicidal) 2 years or more
Depression NOS = does not meet other criteria but with significant impairment of functioning
PTSD = Post-Traumatic Stress Disorder
Re-experiencing traumatic event
Avoidance of situations associated with event
Increased arousal
Social/occupational impairment

PCN Adjustment Disorder
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Adjustment Disorder:
Emotional and/or behavioral symptoms in response to an identifiable stressor, within 3 months of onset
of stressor – symptoms evidenced by:
Marked distress in excess of what would be expected
Social/occupational impairment
Stress-related disturbance does not meet criteria for another diagnosis and is not an exacerbation of
pre-existing diagnosis; does not represent expected bereavement; once stressor has terminated, does
not continue for more than an additional 6 months
Diagnostic criteria:
Onset of symptoms must occur within 1 month of stressor (not unusual or catastrophic)
Manifests behavior disturbances found in any affective disorder (except delusions and
hallucinations), neurotic disorder, stress-related disorder, somatoform disorder, or conduct disorder
BUT criteria for any individual disorder not met
Example symptom features:
Brief depressive reaction, transient, mild, less than 1 month
Mixed anxiety/depression
Predominant conduct disorder
Mixed disturbance of emotion and conduct
Prolonged depressive reaction, mild depressive state occurring in response to prolonged
exposure to stressful situation (not more than 2 years)
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PCN Manic Episode/Hypomaniac Episode (Bipolar I/Bipolar II)
Manic (Bipolar I) Episode:
distinct period during which there is an abnormally and persistently
elevated, expansive, or irritable mood lasting at least 1 week (or less if hospitalization is required
Must be accompanied by at least three (3) of the following symptoms (4 if mood is only irritable);
inflated self esteem/grandiosity, decreased need for sleep, pressurized speech, racing thoughts,
distractibility, psychomotor agitation, excessive involvement in pleasurable activities with a higher
potential for painful consequences, increased involvement in goal-directed activity
Disturbance must be sufficiently severe to cause marked impairment in social and occupational
functioning or to require hospitalization, or is characterized by the presence of psychotic features
Symptoms not due to direct physiological effects of medication, general medical condition, or substance
abuse
Symptoms do not meet criteria for a mixed episode

Hypomanic (Bipolar II) Episode: distinct period during which there is an abnormally and persistently
elevated, expansive, or irritable mood lasting at least 4 days
Must be accompanied by at least three (3) of the following symptoms (4 if mood is only irritable);
inflated self esteem/grandiosity, decreased need for sleep, pressurized speech, racing thoughts,
distractibility, psychomotor agitation, excessive involvement in pleasurable activities with a higher
potential for painful consequences, increased involvement in goal-directed activity
Hypomanic episodes must be clearly different form the usual non-depressed mood and there must be a
clear change in functioning that is not characteristic of usual functioning
Changes in mood and functioning must be observable by others – in contrast to a manic episode, a
hypomanic episode is NOT severe enough to cause marked impairment in social or occupational
functioning, does not require hospitalization or demonstrate psychotic features
Symptoms not due to direct physiological effects of medication, general medical condition, or substance
abuse

PCN Complicated Grief Questionnaire
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Likert scale for each question:
0:
not at all
1:
somewhat
2:
a lot

1. How much of the time are you having trouble accepting the death of a loved one?
2. How much does your grief interfere with your life?
3. How much are you having images or thoughts of your loved one when he or she died or
other thoughts about the death that really bother you?
4. Are there things that you used to do when your loved one was alive that you don’t feel
comfortable doing any more, that you avoid? How much are you avoiding these things?
5. How much are you feeling cut off or distant from other people since your loved one
died, even people you used to be close to, like family or friends?
Score of 5 or greater: consider referral/evaluation/intervention
Duration of symptoms 6-12 months after death

PCN Delerium Definition and Causes
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Delerium Criteria:
corresponds with ICU/CAM
Feature 1 = acute change or fluctuating course of mental status AND
Feature 2 = inattention
Instruct to squeeze hand with letter “A”
SAVEAHAART
AND
Either Feature 3 or Feature 4
Feature 3 = Disorganized Thinking
Use either a or b:
a – will a stone (leaf) float on water
are there fish (elephants) in the sea
does 11/21 pounds weigh more than 21/11 pounds
can you use a hammer to pound a nail (cut wood)
b – hold up this many (2) fingers, now with the other hand
Feature 4 = altered Level of Consciousness (RASS other than 0)
Delerium Differential Diagnosis:
Metabolic
(Ca++, Na+, renal, hepatic, thyroid, O2, glucose)
Infectious
(UTI, Pneum, cellulitis, wound, IVC, CNS)
Comorbidity
(constipation, urine retention, PE, MI, stroke)
Cancer-related
(leptomeningeal, mets, RT, paraneoplastic)
Seizure
(complex, partial, postictal)
Deficiency
(B12, thiamine, HgB)
Recent surgery
(anesthesia, sedation)
Substance
(opioid, benzo, anti-Ach, anti-histamine, NSAID, steroid)
Multi-factorial
Terminal

(restlessness often combination of progressive disease, dehydration,
accumulation of metabolites from organ failure)
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PCN SAS RASS

SAS = Sedation-Agitation Scale (Riker)
7 – dangerous agitation
6 – very agitated
5 – agitated
4 – calm, cooperative
3 – sedated
2 – very sedated
1 – unarousable

RASS = Richmond Agitation-Sedation Scale
+4
+3
+2
+1

combative, violent, dangerous
very agitated, aggressive
agitated, frequent non-purposeful movements
restless, anxious but not aggressive or vigorous

0

alert and calm

-1
-2
-3
-4
-5

drowsy, not fully awake but sustains awake 10 seconds or more
light sedation, brief awake less than 10 seconds
moderate sedation, movement or eyes open to voice but no eye contact
deep sedation, no response to voice but responds to physical stimulation
unarousable, no response to voice or physical stimulation

Cornell Assessment of Pediatric Delerium
Cut point analysis showed the best sensitivity and specificity
for the screening instrument (prioritizing high sensitivity) at
a total CAPD score of 9 or greater. Sensitivity was 94.1% (95%
CI, 83.8–98.8%) and specificity 79.2% (95% CI, 73.5–84.9%). (CCM, 3/14)
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Delerium Observation Screening (DOS) Scale
Scoring:

0 = Never
1 = Sometimes or Always

Observations:
1. Dozes off during conversation or activities
2. Is easily distracted by stimuli from the environment
3. Does not finish question or answer
4. Gives answers that do not fit the question
5. Reacts slowly to instructions
6. Thinks is somewhere else
7. Picking, disorderly, restless
8. Pulls IV tubing, feeding tubes, catheters etc
9. Easily or suddenly emotional
10. Sees/hears things which are not there
Scoring:

1 = Never
0 = Sometimes or Always
11. Maintains attention to conversation or action
12. Knows which part of the day it is
13. Remembers recent events

Less than 3/13 = not delirious
3/13 or greater = probably delirious
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PCN Spiritual Assessment – HOPE

H:
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sources of hope, meaning, comfort, strength, peace, love, connection
What gives you support?
What are your sources of hope….?
What do you hold onto during difficult times?
What sustains you and keeps you going?
For some people religious and spiritual beliefs act as a source of strength and comfort. ? true for you

O:

organized religion
How important is this to you?
What parts are helpful and not so helpful?
Are you part of a faith community?

P:

personal spirituality and practices
Do you have personal/spiritual beliefs that are independent of organized religion?
Do you believe in God?
What aspects of your spirituality or spiritual practices do you find most helpful?

E:

effects on medical care and end-of-life issues
Has being sick affected the things you usually do to help you spiritually?
Are you worried about conflicts between your spiritual beliefs and medical care?
? wish to speak to clergy
? practices/restrictions to know
? influence on EOL care
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PCN Spiritual Assessment FICA Mnemonic

F

faith, belief, meaning
“do you consider yourself spiritual or religious”?
“do you have spiritual beliefs that help you cope with stress”?
“what gives your life meaning”?

I

importance and influence
“what importance does your faith or belief have on your life”?
“have your beliefs influenced you in how you handle stress”?
“do you have specific beliefs that might influence your healthcare decisions”?

C

community
“are you a part of a religious or spiritual community”?
“is there a group of people you really love or who are important to you”?

A

address/action in care
“how should the health care provider address these issues in health care”?

Spirituality = meaning, purpose, something beyond oneself
Qualities of being: hope, love, purpose, meaning
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PCN Spiritual Assessment SPIRIT Mnemonic

S:

spiritual belief system
? formal affiliation
? important

P:

personal spirituality
? in what ways important

I:

integration with a spiritual community
? belong to religious group/community

R:

ritualized practices/restrictions
? specific practices

I:

implications for health care
? discuss religious/spiritual implications of health care

T:

terminal events planning
? particular aspects of medical care to forego because of religion/spirituality
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Cultural Competency and the Role of Race, Ethnicity, and
Religion
Physicians who practice in a multicultural environment have a responsibility to understand that
family members from some cultures may have very different perspectives on the family’s role
and on who should be involved in treatment decisions. Individuals from some cultures may not
endorse tenets of Western clinical ethics, such as the equivalence of withholding and
withdrawing life support or the definition of brain death. It is important to anticipate differences
in perspectives and apply principles of culturally effective end-of-life care to these situations.
Several studies of patients’ attitudes toward end-of-life care identify values that vary by race,
ethnicity, and geographic origin. On average, nonwhites are more likely to request life-sustaining
therapy and are less likely to have advanced directives or do-not-resuscitate orders or accept
hospice care. Much of this difference is influenced by patients’ and families’ lack of trust in
physicians and health-care institutions. Although understanding ethnic variations in preferences
will not solve all problems with end-of-life care, a clearer understanding of what contributes to
patients’ and families’ understanding, fears, and preferences improves communication and is a
crucial step in providing better end-of-life care.
Physicians have a responsibility to avoid stereotyping patients or making assumptions about their
attitudes based solely on race, ethnicity, religion, or other demographic characteristics. Existing
recommendations can help physicians provide end-of-life care that accommodates needs based
on religion and culture.The dying process is one of the most important events in which ritual
aspects of religion and spirituality play a role. During discussions of end-of-life care, time should
be spent discussing, understanding, and accommodating cultural and religious perspectives, and
reasonable efforts should be made to accommodate rituals associated with dying. Physicians
should not assume that physician and hospital staff share the same values as patients and families
of similar religious or ethnic background, and should not substitute statements from persons of
similar background for a more thorough discussion with the patient and their family.
“Cross-cultural” Mnemonics
L earn, listen
E xplain
A cknowledge
R ecommend
N egotiate

E xplanation
T reatment
H ealers
N egotiation
I ntervention
C ollaboration

PCN Questions to Assess Spirituality
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S piritual belief system
P ersonal spirituality
I integration in a spiritual community
R itualized practices and restrictions
I mplications for medical care
T erminal events planning
Hope: “as you look to the future, what are your biggest fears”?
“are there things you might hope for even if you cannot be cured”?
“does the word hope have any spiritual significance for you”?
“would anything be unfinished if you were to die sooner rather than later”?
Meaning:

“what gives your life most meaning”?
“what gives you strength in difficult times”?
“do you have any thoughts about why this happened to you”?
“if your time were limited, what would be most important to you”?

Values: “are you able to hold on to your sense of dignity and purpose”?
“how are others treating you since you became ill”?
Relationships: “how is your family coping with your illness”?
“what is it like to be taken care of by others after being a caregiver for so long”?
“is there anyone you have to make amends with”?
“(if religious) how are things between you and God”?

PCN Spirituality (Doctrinal Justification[s] alternative)
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Hope for Miracle:
All humans are subjects to the laws of nature by the virtue of God’s sovereign rule issued for
people; although God is not bound by the laws of nature, humans are; it is appropriate to accept a
miracle when granted by God, but it is not appropriate to expect it, as this would imply that God follows
human rules and not his sovereign design
One Shall Not Give Up On The God Of Faith:
Continuing with the aggressive treatment no longer constitutes awaiting for God’s will to
manifest itself in a miracle; rather it is interfering with God’s plan made evident in the abundantly given
due time; withholding treatment amounts to acceptance of God’s plan
Life Must Be Preserved At All Costs:
Life given by God is a supreme gift; yet life artificially maintained by a machine is not; the
abundant gift of life includes a promise of presence, personhood,, and participation in the divine vision;
the technology-dependent support of vegetative function discounts the true gift of life
Suffering Is Redemption:
One needs capacities of personhood and free choice in order to elect participation in a
redemptive and transformative suffering; when such a choice is made to and not for a person, suffering
becomes an end in itself

PCN ESAS (Edmonton Symptom Assessment Scale)
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No Symptom___1___2___3___4___5___6___7___8___9___10 Worst Possible Symptom

Pain
Fatigue
dyspnea
Nausea
Constipation
Depression
Anxiety
Drowsiness
Appetite
Well-Being
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PCN Mental Status Examination Terms
Appearance and Behavior:
Grooming, clothing, hair, nails
Attitude to situation/examiner – hostile, withdrawn, seductive
Motor – slow, restless, tremors, bizarre
Speech:
Slow, pressured, monotonous
Volume – loud, quiet, slurred
Quantity – restricted/excessive, spontaneous
Mood/Affect:
Depressed, euphoric, suspicious, labile
Restricted, flattened, inappropriate
Form of Thought:
Amount and rate of production – hesitant, vague, flight of ideas
Continuity of ideas – logical order of the flow of ideas
Content of Thought:
Delusions – persecution, poisoning
Suicidal thoughts/plans/intent
Other – obsessions, compulsions, hypochondriacal preoccupation
Perception:
Hallucinations – sound, vision, smell, taste, tactile, somatic
Other – derealization, depersonalization, heightened/dulled
Sensorium and Cognition:
Level of Consciousness (LOC) – abnormal drowsiness, clouding, delirium
Memory – immediate recent, remote
Orientation – time, place, person
Concentration – serial 7s
Abstract thinking
Insight:
Extent of awareness of problem(s)
Compliance with intervention(s)
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PCN Abbreviated Mental Status Score
1
2
3
4
5
6
7
8
9
10

age
time (nearest hour)
address (repeated at end of exam)
year
name of current location
recognition of two persons
date of birth
year World War I started
name of president
count backwards from 20 to 1

6 or less correct consistent with dementia
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PCN Short Test of Mental Status (STMS)
Orientation:
Attention:
Immediate
Recall:

0-8 points
Name, address, current location (building), city, state, date (day), month
0-7 points
Present 5, then 6, then 7 digits to repeat
2-9-6-8-3
5-7-1-9-4-6 2-1-5-9-3-6-2

0-4 points
Present four(4) unrelated words to repeat (subtract #trials needed to learn)
“apple, Mr Smith, charity, tunnel”
Calculation: 0-4 points
5x13 65-7 58/2 29+11
Abstraction: 0-3 points
Describe similarity:
Orange – banana
Dog – horse
Table – bookcase
Construction and Copying: 0-4 points (2 points each)
Draw a clock face showing 11:10
Copy a cube
Information: 0-4 points
President
1st president
Define an island
Number of weeks in a year
Recall:
0-4 points
“apple, Mr Smith, charity, tunnel”
38 possible points
34-38 – normal
29-33 – cognitive impairment
28 or less - dementia
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PCN MMSE Mini-Mental-Status Exam
Orientation:
year/season/date/day/month
state/country/town/hospital/floor

Points
5
5

Registration:
name three objects – 1 second to say each
(i.e. ball, flag, tree)
ask patient to repeat all three after you have said them

3

then repeat them until patient learns all three, count trials
Attention/Calculation:
serial 7’s – up to 5 answers OR
spell WORLD backwards (DLROW)

5

Recall:

3
ask for the three objects repeated above

Language:
show/name a pen and watch
“repeat – no ifs, ands, or buts”
follow a 3 stage command:
take a paper in your hand
fold it in half
place it on the floor
read and obey
“CLOSE YOUR EYES”
“write a sentence”
“copy the design” (intersecting pentagons)

Cognitive Function:
24-30 normal
19-23 mild
10-18 moderate
<10
severe

2
1

3
1
1
1
30
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PCN Neuro-Cognitive Behavioral Assessment Terms
Mental Status
Oriented:
Inattention:

aware of person, place, time, season
difficult in focusing attention
easily distracted
difficulty in following conversation
Disorganized Thinking:
incoherent, rambling, irrelevant
unclear, illogical flow of ideas
Altered Level of Consciousness (LOC):
vigilant – startled easily
lethargic – repeatedly dozes off but responds to touch or voice
stuporous – very difficult to arouse
comatose – cannot be aroused
Psychomotor Retardation:
unusually decreased level of activity
sluggish
staring into space
sitting/lying in one position

Cognitive Skills for Daily Decision-Making
Independent: decisions consistent and reasonable
Modified Independence:
some difficulty in new situations only
Moderately Impaired:
decisions poor
cues and/or supervision required
Severely Impaired:
never or rarely makes decisions

PCN General Symptom Distress Scale (GSDS)
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1. Symptoms present:
depression
anxiety
fatigue
dyspnea
nausea
vomiting
pain
sleep difficulty
bowel problems
difficulty concentrating
loss of appetite
cough
2. Rank (1,2,3,……..) of symptoms present – from most distressing to next most distressing……
3. On a scale of 1 to 10, in general how distressing are ALL of your symptoms to you?
1 – not at all
10 – extremely
4. On a scale of 1 to 10, how well are you able to manage your symptoms?
1 - cannot manage
10 - manage extremely well
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PCN Fall Risk Assessment
Points
7
3
3
3
3

2
2
2
4
6
Very High Risk
High Risk
Medium Risk
Low Risk

history of a fall within past 12 months
altered elimination – incontinence, frequency, urgency
cognitive impairment – inability to recall recent events
Confusion, impaired judgment
sad, depressed
intrinsic factors
orthostatic hypotension
syncope
arrhythmia
peripheral neuropathy
seizure history
parkinsons
hx stroke
neuromuscular disorder
communication – HOH, language barrier, tracheostomy
visual impairment
diuretics or laxatives
anti-hypertensive medication
opioid medication
19 points or greater
14-18 points
10-13 points
9 points or less
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PCN Functional Activities Questionnaire
Score each question on a 4 point scale:
0 = normal, 1 = does with difficulty, 2 = requires assistance, 3 = dependent
In the past 4 weeks, did the patient have any difficulty or need help with:?
1
2
3
4
5
6
7
8
9
10

writing checks, paying bills, keeping financial records
assembling tax records, business affairs, papers
shopping alone – clothes, household, groceries
playing a game of skill or working on a hobby
heating water, making coffee, turning off stove
preparing a balanced meal
keeping track of current events
paying attention to, understanding, or discussing a TV program/book/magazine
remembering appointment, family occasion, holiday, medication
traveling out of the neighborhood, driving, arranging to take bus

normal = 0-1
mild cognitive impairment = 4-9
mild dementia = 10-13
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PCN Spinal Cord Injury Assessment
Level of Innervation Sensory

Muscle Group

C4
C5
C6
C7
C8

acromioclavicular joint
lateral antecubital fossa
thumb
middle finger
little finger

diaphragm
shoulder rotators/abductors; elbow flexor
supinators, pronators, wrist extensor
elbow extensor, wrist flexor
finger flexors, distal phalanx

T1

medial antecubital fossa

intrinsic hand muscles

L2
L3
L4
L5
S1
S2-5

upper anterior thigh
medial femoral condyle
medial malleolus
dorsum of foot
lateral heel
peri-anal

hip flexor
knee extensor
ankle dorsiflexor
toe extensors
plantar flexors
sphincter

PCN Modified Medical Research Council (mMRC) Dyspnea Scale
0:
1:
2:
3:
4:
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breathless with strenuous exercise
short of breath when hurrying on level ground or walking up a slight hill
on level ground, walking slower than people of same age because of breathlessness
or have to stop for breath when walking at my own pace
stop for breath after walking about 100 yards or after a few minutes on level ground
too breathless to leave the house; breathless when dressing
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Function Assessment: Activities of Daily Living (ADL)

Bathing
Dressing
Toileting
Transferring
Continence
Feeding

receives either no assistance or assistance in bathing only one part of the body
gets clothes and dresses without any assistance except for tying shoes
goes to toilet room, uses toilet and returns without assistance
(may use cane or walker and may use bedpan or urinal at night)
moves in and out of bed and chair without assistance
(may use cane or walker)
controls bowel and bladder completely by self, without occasional accidents
feeds self without assistance
(except for help with cutting meat or buttering bread)

Function Assessment: Instrumental Activities of Daily Living
Use telephone
Shop
Prepare food
Clean house
Laundry
Use transportation
Take medications
Manage finances
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Function Assessment
Eastern Cooperative Oncology Group (ECOG)

Performance Status

0

Fully active, able to carry out all pre-disease performance without restriction

1

Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or
sedentary nature (light house work, office)

2

Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about
more than 50% of waking hours

3

Capable of only limited self-care, confined to bed or chair more than 50% of waking hours

4

Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair

5

Dead
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PCN Function Assessment FAST
Functional Assessment Staging

(dementia, cognitive impairment)

5
6A
6B
6C
6D
6E

requires assistance in choosing proper clothing to wear for day/season/occasion
improperly putting on clothes without assistance
unable to bathe properly occasionally or more often over past weeks
inability to handle mechanics of toileting occasionally or more often over past weeks
urinary incontinence occasionally or more often
fecal incontinence occasionally or more often over past week

7A
7B
7C
7D
7E
7F

ability to speak limited to approximately 6 words or fewer in the course of a day
speech ability limited to use of a single intelligible word in a day (may be repeated)
ambulatory ability is lost; cannot walk without personal assistance
cannot sit up without assistance; will fall without lateral support
loss of ability to smile
loss of ability to hold head up independently

Based on highest CONSECUTIVE level of disability
5

correlates with moderate dementia

6

correlates with moderately severe

7

correlates with severe

7

roughly correlates with 6 month prognosis
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PCN Function Assessment CDT
Clock-Drawing Test
Step 1 give patient a sheet of paper with a drawn large circle
Step 2 instruct to draw numbers in the circle to look like the face of a clock;
then draw the hands of the clock to read “10 after 11”
Scoring:
1
perfect
2
minor visual-spatial errors

no errors
mildy impaired spacing of numbers
draws numbers outside of circle
turns page > draws numbers upside down
draws with lines (“spokes”)

3

inaccurate representation
of 10 after 11 when visualspatial organization is
perfect or minor deviation

minute hand points to 10
writes “10 after 11”
unable to make any notation of time

4

moderate visual-spatial
disorganization of times
such that accurate notation
of 10 after 11 not identified

moderately poor spacing
omits numbers
perseveration
counterclockwise
dysgraphia

5
6

severe level of disorganization
no reasonable representation
of a clock

as in 4
no attempt
no semblance of a clock
writes a word or name

(3 or greater = cognitive deficit)
High NEGATIVE predictive value (95%) > normal CDT strong argument against cognitive deficit
Requires comprehension, visual-spatial ability, reconstruction skills, concentration, numerical
knowledge, visual memory, executive function; not biased by age, gender; not influenced by language
limitation or altered mood
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Function Assessment: Karnofsky Performance Status Score (KPS)

Karnofsky Score

Level of Functional Capacity

100

normal, no complaints, no evidence of disease

90

able to carry out normal activity, minor signs/symptoms of disease

80

normal activity with effort, some signs or symptoms of disease

70

cares for self, unable to carry on normal activity or to do active work

60

requires occasional assistance but is able to care for most needs

50

requires considerable assistance and frequent medical care

40

disabled, requires special care and assistance

30

severely disabled, hospitalization indicated although death not imminent

20

hospitalization necessary, very sick, active supportive treatment necessary

10

moribund, fatal processes, progressing rapidly

0

dead
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Function Assessment: modified Rankin score (m-R)

0

no symptoms

1

no significant disability despite symptoms – able to carry out all usual activities

2

slight disability – unable to carry out all previous activities but able to carry
out ADLs without assistance

3

moderate disability – requiring some help but able to walk without assistance

4

moderately severe disability – unable to walk without assistance and unable
to carry out ADLs without assistance

5

severe disability – bedridden, incontinent, requiring constant nursing care and attention

6

dead
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PCN Glasgow Coma Scale (GCS)

Eye opening response:
Spontaneous – open with blinking at baseline
Opens to verbal command, speech or shout
Opens to pain, not applied to face
None

4 points
3 points
2 points
1 point

Verbal response:
Oriented
Confused conversation, but able to answer questions
Inappropriate responses, words discernible
Incomprehensible speech
None

5 points
4 points
3 points
2 points
1 point

Motor response:
Obeys commands for movement
Purposeful movement to painful stimuli
Withdraws to pain
Abnormal (spastic) flexion, decorticate posture
Extensor (rigid) response, decerebrate posture
None

6 points
5 points
4 points
3 points
2 points
1 point
________
Max 15 points
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PCN Function Assessment
Palliative Performance Scale (PPS)
%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

100
Full
Normal/no evidence
Full
Normal
Intact

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

90
Full
Normal/some
Full
Normal
Intact

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

80
Full
Normal with effort/some
Full
Normal or reduced
Intact

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

70
Reduced
Unable to do normal/some
Full
Normal or reduced
Intact or confusion

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

60
Reduced
Unable to do hobby or some housework/significant
Occasional assist
Normal or reduced
Intact or confusion
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%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

50
Mainly sit/lie
Unable to do any work/extensive
Considerable assist
Normal or reduced
Intact or confusion

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

40
Mainly in bed
Unable to do any work/extensive
Mainly assist
Normal or reduced
Intact, drowsy, or confusion

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

30
Bed bound
Unable to do any work/extensive
Total care
Reduced
Intact, drowsy, or confusion

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

20
Bed bound
Unable to do any work/extensive
Total care
Sips
Intact, drowsy, or confusion

%:
Ambulation:
Activity/Evidence of Disease:
Self-Care:
Intake:
LOC:

10
Bed bound
Unable to do any work/extensive
Total care
Mouth care
Drowsy or coma

Instructions for PPS
Begin at the left column and read downward until the appropriate ambulation level is reached, then read across to the next column and
downwards again until the activity/evidence of disease is located. These steps are repeated until all five columns are covered before assigning
the PPS. Leftward columns (ambulation on left>activity level/evidence of disease>self-care>intake>LOC on right) are “stronger” determinants
and take precedence over others to the right. PPS scores are in 10% increments. Choosing a “half-fit” level (such as 45%) is not correct. The
combination of clinical judgment and “leftward” precedence determines the score. PPS may be used for: communication regarding functional
status, criterion for workload assessment or other measurements/comparisons, and as a prognostic indicator.
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Edmonton Frail Scale
Domain

Item

Score

Cognition

Please imagine that this pre-drawn circle is a clock.
Please place the numbers in the correct positions and
Then place the hands to indicate a time of
“ten past eleven”

0 – no errors
1- minor spacing errors
2- other errors

General
Health
Status

In the past year how many times have you been
admitted to the hospital?

0-0, 1-1, 2- 2 or more

In general, how would you describe your health?

0-excellent, very good , or good
1-fair, 2-poor

Functional
With how many of the following activities do you
Independence help: meal preparation, shopping, transportation,
telephone, housekeeping, laundry, managing money,
taking medications?

0-1, 1-2 to 4, 2-5 to 8

Social Support When you need help, can you count on someone who
is willing and able to meet your needs?

0-always, 1-sometimes, 2-never

Medication Use Do you use five or more prescriptions on a regular basis?
At times do you forget to take your prescription medications?

0-no, 1-yes
0-no, 1-yes

Nutrition

Have you recently lost weight so that your clothing has
become looser?

0-no, 1-yes

Mood

Do you often feel sad or depressed?

0-no, 1-yes

Continence

Do you have a problem with losing control of urine when
You don’t want to?

0-no, 1-yes

Functional

Please sit in this chair with your back and arms resting.
When I say “go”, please stand up and walk to the mark on
the floor (approximately 10 feet away), then turn around,
return to the chair and sit down.

0-10 seconds or less
1-11 to 20 seconds
2->20 seconds or
unwilling, unable

Scoring:
0-5
6-7
8-9
10-11
12-17

not frail
vulnerable
mild frailty
moderate frailty
severe frailty
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PCN Malnutrition Categories
Severe:
Albumin
Prealbumin
Ideal body weight
Usual body weight
BMI
Moderate:
Albumin
Prealbumin
Ideal body weight
Usual body weight
BMI

< 2.0 g/dl
< 5.0 mg/dl
<70%
<75% or *
<16

< 2.5 g/dl
< 10.0 mg/dl
<80%
<85%
<17

Mild:
Albumin
Prealbumin
Ideal body weight
Usual body weight
BMI

< 3.0 g/dl
< 15.0 mg/dl
<90%
<95%
<18.5

*unintended weight loss of > 5% in one month, >7.5% in 3 months, >10% in 6 months, or
>20% in one year
“chronic” malnutrition is defined as a duration of three months or more.
At least two indicators should be present in addition to physical findings and high-risk clinical
circumstances. Albumin and prealbumin should be considered one indicator, not two.

PCN Cerebral Performance Categories (CPC Scale)
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CPC 1: good cerebral performance – conscious, alert, able to work, might have mild neurologic or
psychologic deficit
CPC 2: moderate cerebral disability – conscious, sufficient cerebral function for independent activities
of daily life, able to work in sheltered environment
CPC 3: severe cerebral disability – conscious, dependent on others for daily support because of
impaired brain function, ranges from ambulatory state to severe dementia or paralysis
CPC 4: coma or vegetative state – any degree of coma without the presence of all brain death criteria;
unawareness, even if appears awake (vegetative state) without interaction with environment, may have
spontaneous eye opening and sleep/awake cycles, cerebral unresponsiveness
CPC 5: brain death – apnea, areflexia, EEG silence

PCN Function Assessment Barthel Index
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Activity
Feeding:
0 = unable
5 = needs help cutting, spreading butter etc, or requires modified diet
10 = independent
Bathing:
0 = dependent
5 = independent (or in shower)
Grooming:
0 = needs help with personal care
5 = independent face/hair/teeth/shaving
Dressing:
0 = dependent
5 = needs help but can do about half unaided
10 = independent (including buttons, zips, laces)
Bowels:
0 = incontinent (or needs to be given enemas)
5 = occasional accident
10 = continent
Bladder:
0 = incontinent, or catheterized and unable to manage alone
5 = occasional accident
10 = continent
Toilet Use:
0 = dependent
5 = needs some help
10 = independent (on and off, dressing, wiping)
Transfers:
(bed to chair and back)
0 = unable, no sitting balance
5 = major help (one or two people, physical) can sit
10 = minor help (verbal or physical)
15 = independent
Mobility:
(on level surfaces)
0 = immobile or less than 50 yards
5 = wheelchair independent, including corners, more than 50 yards
10 = walks with help of one person (verbal or physical) more than 50 yards
15 = independent
Stairs:
0 = unable
5 = needs help (verbal, physical, carrying aid)
10 = independent
0 – 100 points
Record what patient actually does; need for supervision > not independent; usually last 24-48 hrs
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PCN Prognostic Assessment
Non-Disease Specific
Population:

Hospitalized, age 70 or greater

Burden of Illness Score (BIS)
BIS variables

BIS points

High-risk diagnoses
See below

0-3

Albumin < 3.5
Creatinine > 1.5
Dementia
Walking impairment

1
1
1
1
(Scoring for High-risk diagnoses)
Variable
points
Lymphoma
Leukemia
6
Acute renal failure
5
Cancer
Stroke
CHF
COPD
Chronic renal failure 2
DM with organ disease
Pneumonia
(Transfer High-risk diagnoses score to BIS:
0
1-2
3-5
6 or greater

Correlation of BIS Score with 1-year mortality risk %
0-1
2
3
4 or greater

8
24
51
74

6

3
2
2
2
1
1
0
1
2
3
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Prognosis Assessment

Non-Disease Specific

CARING criteria
Population:

Criteria on day of admission to acute care hospital

Caring criteria components:

C:

Primary Diagnosis of Cancer
Cancer diagnosis is primary reason for admission including admission for chemoRx

A:

Admitted to the hospital 2 or more times in the past year
for the same chronic illness or complication of that illness

R:

Resident in a Long-Term Care or Skilled Nursing Facility (Nursing Home)

I:

ICU admission with Multiple Organ System Failure (MOF)
MOF = any two or more of the following
Mechanical ventilation
Pressor support for hypotension
Renal replacement therapy (RRT) indicated or already started

NG:

Presence of two or more items from one category of non-cancer hospice guidelines
Categories
Items
Renal

Dementia
Stop/decline dialysis
Not transplant candidate
Urine output < 40ml/24 hours
Creatinine > 8.0
Creatinine clearance 10 ml/min or less
Uremia
Persistent K+ > 7.0
One or more comorbid conditions:
Cancer
Congestive Heart Failure
Chronic Lung Disease
Sepsis
Cirrhosis
HIV/AIDS

Unable to ambulate independently
Urinary or fecal incontinence
Unable to speak with more than single words
Unable to bathe independently
Unable to dress independently
One or more comorbid conditions:
Aspiration pneumonitis
Pyelonephritis
Decubitus ulcer
Difficulty swallowing
or refusal to eat
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Cardiac

Pulmonary
Ejection Fraction < 20%
Symptoms despite diuretic/vasodilator
Not transplant candidate
History of cardiac arrest
History of syncope
Systolic BP < 120
CVA of cardiac origin
One or more comorbid conditions:
Cancer
Chronic Lung Disease
Sepsis
Cirrhosis
HIV/AIDS

Liver

Dyspnea at rest
FEV1 < 30%
Frequent ER or hospital admits for
pulmonary infection or respiratory distress
SaO2 < 88% on O2
Cor pulmonale
pCO2 > 50
Resting tachycardia > 120
One or more comorbid conditions:
Cancer
Congestive Heart Failure
Sepsis
Cirrhosis
HIV/AIDS

Stroke/CVA
End-stage cirrhosis
Not transplant candidate
Protime > 5 sec and albumin <2.5
Ascites unresponsive to treatment
Hepatorenal syndrome
Hepatic encephalopathy
SBP
Recurrent variceal bleed
One or more comorbid conditions:
Cancer
CHF
Chronic Lung Disease
Sepsis
Cirrhosis
HIV/AIDS

HIV/AIDS
Persistent decline in function
Chronic diarrhea
Decision to stop treatment
CNS lymphoma
Systemic lymphoma
Dilated cardiomyopathy
CD4 < 25 with disease progression
Viral load > 100,000

Coma at onset
Coma > 3 days duration
Limb paralysis
Urinary/fecal incontinence
Impaired sitting balance
KPS < 50%
Recurrent aspiration
Age > 70
One or more comorbid conditions:
Cancer
CHF
Chronic Lung Disease
Sepsis
Cirrhosis
HIV/AIDS

Neuromuscular
Diminished respiratory function
Chosen not to receive BiPAP/MV
Difficulty swallowing
Diminished functional status
Incontinence
One or more comorbid conditions:
Cancer
CHF
Chronic Lung Disease
Sepsis
Cirrhosis
HIV/AIDS

Caring Criteria Components [or combination(s) of components] predicting 1-year mortality probability
of 0.49 or greater (49 % or greater):
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Caring Criteria Components [or combination(s) of components] predicting
1-year mortality probability of 0.49 or greater (49 % or greater):
Age < 55:

A and/or R Plus C and/or I and or NG

Age 55-65: A and/or R Plus C and/or I
NG

Age 66-75: A and/or R Plus C and/or I
NG

Age > 75:

A plus R
C
I
NG
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PCN Prognostic Assessment
Non-Disease Specific

Charlson Comorbidity Index (CCI)

Score = total points
Comorbidity component (# points)
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia
COPD
Connective tissue disease
Peptic ulcer disease
Diabetes mellitus-uncomplicated
Diabetes mellitus-end organ damage
Chronic kidney disease-moderate to severe
Hemiplegia
Leukemia
Malignant lymphoma
Solid tumor
Solid tumor-metastatic
Liver disease-mild
Liver disease-moderate to severe
AIDS

(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(2)
(6)
(1)
(3)
(6)
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PCN Prognostic Assessment
Non-Disease Specific
Population:

Newly Admitted Nursing Home Residents

Mortality Risk Index Score (MRIS)
MRIS variables

MRIS Points

Presence of cancer
Shortness of breath
CHF
Bedbound
Male
Unstable conditions
<75% of food eaten
Low functional ability score
Swallowing problem
Bowel incontinence
BMI < 23

2.43
2.15
1.66
1.99
1.42
1.59
1.75
1.77
1.41
1.44

Correlation of MRIS points with 1-year mortality risk %
0-1
11.4
2-3
20.2
4-5
32.3
6-7
44.5
8-9
55.9
10-11
69.0
12-13
81.7
14-15
87.6
16-17
95.4
18-19
100
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PCN Prognosis Assessment
Non-Disease Specific
Population:

Hospital Palliative Care Consults

Palliative Prognostic Score (PaP):

30-day survival probability

PaP Variables

PaP points

Dyspnea

Yes
No
Anorexia
Yes
No
KPS
30 or greater
Less than 30
Total WBC
4.8-8.4
8.5-11
> 11
Lymphocyte% 20-40
12-19.9
<11.9
Clinician
Prediction
#Weeks
Survival
>12
11-12
7-10
5-6
3-4
1-2

1
0
1.5
0
0
2.5
0
0.5
1.5
0
1.0
2.5

Total Possible

17.5 points

0
2
2.5
4.5
6
8.5

Correlation of Points score with 30 day mortality %
0-5.5
5.6-11.0
11.1-17.5

>70%
30%-70%
<30%
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PCN Prognostic Assessment
Non-Disease Specific
Population:

Community Hospital (age 70 or greater, excluding ICU, LOS less than 2 days)

Prognostic Index 1-yr Mortality Older Adults (PIMOA)
PIMOA variables

PIMOA points

Male
ADL Dependence at discharge
1-4 ADLs
All ADLs
CHF
Cancer-localized
Cancer-metastatic
Admission creatinine
3.0 or greater
Admission albumin
3.0-3.4
<3.0

1
2
5
2
3
8
2
1
2

Correlation of total points with 1-year mortality risk %
0-1
4
2-3
19
4-6
34
>6
63
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PCN Prognosis PPS
Prognostic Assessment PPS (Palliative Performance Scale)
Population:

Non-disease specific
Community Palliative Program Consults
Acute care
LTC
In-patient hospice unit

Survival Rate %
#days: 1

3

5

7

14

30

45

60

90

180

365

PPS(%)
80

100

100

100

100

100

100

81

75

46

35

10

70

100

97

96

95

94

82

76

68

57

36

12

60

100

100

100

98

91

65

52

41

25

10

7

50

100

97

94

91

76

57

41

33

14

4

0

40

98

97

96

88

73

50

36

27

16

8

1

30

97

87

71

63

42

23

22

17

11

2

0

20

92

72

53

42

19

8

6

5

4

0

0

10

52

33

19

13

5

0

0

0

0

0

0
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PCN Prognosis Assessment PALIAR
6 month mortality % for patients with Advanced Chronic Medical Conditions:
Chronic heart failure, NYHA III-IV
Chronic lung failure, dyspnea stage 3+, sat <90% RA or chronic O2
Chronic renal failure, GFR<30, creat 3 or greater
Chronic liver failure, Child-Pugh > 7
Chronic neurologic disease with cognitive impairment (18 or less MMSE) or
functional impairment (Barthel Index < 60)

Characteristics

PALIAR score

85 years old or more
Anorexia
Dyspnea at rest
Pressure ulcer(s)
Serum albumin < 2.5
ECOG 3 or more

3
3.5
3.5
3
4
4

0 – 21 points

Correlation with observed mortality(% in 6 months):
Points
0
3
3.5
4
6-6.5
7-7.5
8-10.5
11-21

% mortality 6 months
21
25
37
39
43
47
65
67
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PCN Prognostic Assessment
Non-Disease Specific
Parameters of Prognosis Time Estimate

Hours to Days

less than 4 days

Days to Weeks

4 to 30 days

Weeks to Months

31 to 180 days

Months to Years

more than 181 days
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PCN Chemotherapy Response and Survival Data

Patients with diagnosis of solid organ cancer who were in good enough health to participate in clinical
trial > ambulatory and good functional status)
Response rate %
______________
Breast

25-55

Median Duration of Response Median Survival
(months)
(months)
8-12

24-36

Lung (Nonsmall Cell)
Squamous
24-36
Nonsquamous 20-25

4-6
4-6

6-11
10-12

Esophagus

30-50

4-6

6-9

Gastro-Esophageal
Junction

40-60

6-8

9-12

HER2 negative 20-40
HER2 positive ~50

4-7
6-7

6-11
12-14

20-32

4-6

8-11

Hepatocellular 25-40
HCC
Nonhepatitis C
related HCC
Hepatitis C
related HCC

2-5

Gastric

Pancreas
Liver

6-10
14

Biliary-Cholangiocarcinoma 20-35

4-8

9-14

Colon

30-45

8-10

16-21

Melanoma

15-40

4-14

6-15
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Prognosis Assessment: Disease specific, all cancers
Palliative Prognostic Index (PPI)
Population:

cancer patients in palliative care unit

Variable

Points

PPS
10-20
30-50
60 or greater

4.0
2.5
0

Oral Intake
Severely reduced
(less than mouthfuls)
Moderately reduced
Normal

2.5
1.0
0

Edema
Present
Absent

1.0
0

Dyspnea at rest
Present
Absent

3.5
0

Delirium
Present
Absent

4.0
0

Risk Groups:

A(PPI 2 or less)

Expected Survival:

PPI more than 6
PPI more than 4

B(PPI more than 2 up to 4)
less than 3 weeks
less than 6 weeks

C(more than 4)
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KPS Mortality Prediction
Patient population:

Hospice patients with cancer

Predicted Survival in Days

KPS(%)

10-20

30-40

50 or greater

50% Dead 90% Dead

50% Dead 90% Dead 50% Dead 90% Dead

0

53

115

1

38-46

168-199

2

29-38

3

# Symptoms
232

172

450

83-98 362-428

125-191

450

128-165

63-82 275-356

95-123

413-450

23-30

101-131

50-62 218-270

75-93

328-406

4

19-23

10-95

41-49 181-215

62-74

272-322

5

16

36

54

234

72

Symptoms:
Dry mouth
Dyspnea
Anorexia or difficulty eating
Trouble swallowing
Weight loss

450

156
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Cancer Presentations with a Median Survival of Six Months or Less
Breast
Any metastatic breast carcinoma with one or more of the following:
KPS < 60, ECOG >2
Ca++ > 11.2
Spinal cord compression with decreased ability to walk
C-reactive protein > 10 and albumin < 3.5
Peritoneal or leptomeningeal metastases
Any metastatic breast carcinoma with three or more of the following:
KPS < 80, ECOG > 2
LDH > 500
Any liver metastasis
2 different sites of metastasis
Disease free interval from presentation to metastases < 24 months
Recurrent or refractory disease after initial chemoRx
ER - , PR –
Metastatic breast carcinoma and brain metastases with one or more of the following:
KPS < 80, ECOG > 2
2 or more brain metastases plus extracranial metastases
ER -, PR –
Brain (Glioblastoma)
with one or more of the following:
KPS < 70, ECOG > 2
Suboptimal resection or unresectable
Progressive or refractory despite initial treatment
with two or more of the following:
KPS < 90, ECOG > 1
Age > 55
Recurrent disease after initial treatment
Lesion in critical hemispheric region
Tumor volume > 50cm3 before resection
Hgb < 12
Platelet count > upper limit of normal
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Colorectal
Metastatic colorectal carcinoma with one or more of the following:
KPS < 70, ECOG 2 or greater
Age > 75
Brain metastases with KPS < 80, age > 70
Metastatic colorectal carcinoma with two or more of the following:
KPS < 90, ECOG 1 or greater
Peritoneal carcinomatosis
More than 2 metastatic sites
Malignant ascites
Refractory disease after chemoRx

Esophageal/Gastric
Locally advanced or metastatic esophageal/gastric with one or more of the following:
KPS < 80, ECOG > 1
Recurrent or refractory disease with disease-free interval < 6 months
Locally advanced or metastatic esophageal/gastric with two or more of the following:
KPS < 90, ECOG 1 or greater
Liver or peritoneal metastases
Alkaline phosphatase > 100
LDH > 200
Hgb < 11
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Hepatobiliary/Pancreatic Carcinoma
Locally advanced or metastatic biliary tract or pancreatic with one or more of the following:
KPS < 90, ECOG 1 or greater
Total bilirubin > 10
Recurrent or refractory after initial chemoRx
Liver, peritoneal, or distant metastases
Portal vein thrombosis
Albumin < 3.5
LDH > 500
Episode of DVT or PE
Malignant ascites

Any hepatocellular carcinoma with one or more of the following:
KPS < 60, ECOG > 2
Tumor diameter > 10 cm
Any brain metastasis

Unresectable locally advanced or metastatic hepatocellular carcinoma with two or more of the
following:
KPS < 90, ECOG 1 or greater
Extrahepatic metastases
Symptomatic cirrhosis:
Jaundice
Ascites
Fatigue
bleeding
AFP > 400
Portal vein thrombosis
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Head and Neck Squamous Cell
Recurrent, refractory, or metastatic head and neck squamous cell carcinoma with one or more
of the following:
KPS < 90, ECOG 1 or greater
Recurrence of disease with any metastasis
Greater than 10% weight loss
Muscle invasion or residual tumor at primary site
Pretreatment Hgb < 11
Ca++ > 11.2

Thyroid
Anaplastic thyroid cancer with one or more of the following:
Extracapsular extension or metastases
Unresectable disease or incomplete resection

Melanoma
Advanced or metastatic melanoma with one or more of the following:
KPS < 80, ECOG 2 or greater
LDH x 2 upper limit of normal
Ca++ > 11.2
Metastases to brain or spine
Metastases to liver and one other site

89
NSCLC
Any locally advanced or metastatic NSCLC with one or more of the following:
KPS < 70, ECOG > 2
Weight loss of 5% or albumin < 3
Liver metastases
Bone metastases
CNS metastases with symptoms, age > 65
Pericardial involvement
Pleural effusion with evidence of distant metastases
Hgb < 12
Ca > 11

(SCLC)
Extensive Disease: median survival 6-12 months with Rx, 4 months without Rx
Female Genital
Locally advanced or metastatic ovarian/endometrial/cervical with regional or distal spread and
one or more of the following:
KPS < 60, ECOG > 2
Ca++ > 11.2
2 or more brain metastases
Bowel obstruction without successful repair or urinary tract obstruction
Unresectable disease
Locally advanced or metastatic ovarian/endometrial/cervical with regional or distal spread and
two or more of the following:
KPS < 80, ECOG > 1
Recurrent or refractory disease
Disease-free interval < 6 months (diagnosis to recurrence)
Suboptimal resection with bulky residual disease
Weight loss > 5%
Extra-abdominal metastases
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Male Genital
Hormone-refractory metastatic prostate cancer with one or more of the following:
KPS < 60, ECOG > 2
Hgb < 10
Spinal cord compression with decreased ability to walk
Bladder and Renal Cell
Locally advanced or metastatic bladder or renal cell cancer with one or more of the following:
KPS < 70, ECOG > 2
Greater than 2 brain metastases
Ca++ > 11.2
Locally advanced or metastatic bladder or renal cell cancer with three or more of the following:
KPS < 80, ECOG 2 or greater
Hgb < 11.5
LDH > 300
Disease-free interval < 1 year
Visceral metastases

91
Solid Cancers in general
Any locally advanced or metastatic solid cancer with one or more of the following:
KPS < 60, ECOG > 2
Ca++ > 11.2
Episode of DVT or PE
Any brain metastasis with KPS < 70
More than 2 brain metastases and extracranial metastasis
Spinal cord compression with decreased ability to walk
Malignant pericardial effusion
Unknown Primary
Any metastatic adenocarcinoma or undifferentiated carcinoma of unknown primary with one or
more of the following:
KPS < 80, ECOG > 1
Hepatic, bone, or adrenal metastases
Recurrence of disease after chemoRx
Albumin < 3.5 or weight loss of > 10% in 6 months
Acute Leukemia
Acute Lymphoblastic or myeloid leukemia with one or more of the following:
Age > 70
Extramedullary disease involving Central Nervous System
Refractory to 2 or more courses of chemoRx
Recurrence with disease-free interval of < 14 months
Acute Lymphoblastic or myeloid leukemia with two or more of the following:
Age > 60
KPS < 80, ECOG 2 or greater
Central Nervous System involvement
Evidence of hemorrhage or infection
WBC > 25
LDH > 500
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Chronic Leukemia
Chronic myeloid leukemia in blast transformation with one or more of the following:
Age > 50 with predominant myeloid origin
Myeloid blast transformation with WBC > 50, plt < 100, or Hgb <10
Greater than 50% blasts in peripheral blood
Chronic lymphocytic leukemia with one or more of the following:
Refractory to initial chemoRx
Recurrent disease after 2 or more courses of chemoRx

Lymphoma/Multiple Myeloma
Non-Hodgkins lymphoma or multiple myeloma with one or more of the following:
Secondary extranodal or extramedullary involvement of CNS
Primary CNS lymphoma related to HIV
Aggressive non-Hodgkins lymphoma or multiple myeloma that is refractory or recurrent after
initial treatment – with 2 or more of the following:
KPS < 70, ECOG 2 or greater
Age > 65
LDH above normal
albumin < 3
multiple myeloma with plt < 80
multiple myeloma with serum creatinine 2 or greater
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Non-Cancer Presentations with a Median Survival of Six Months or Less
Heart Failure
Hospitalization for moderate to severe symptomatic heart failure (HF), NYHA (New York Heart
Association) Class III or IV with three or more of the following:
Age > 70
Left Ventricular Ejection Fraction (LVEF) 20% or less
Beta-type Natriuretic Peptide (BNP) > 950
Cardiac troponin I > 0.4
C-reactive protein > 3.5
4th hospitalization for CHF or repeat hospitalization within 2 months
Dependency of 3 or more ADL (activities of daily living) or need for home care
Weight loss of 2.3 kg or greater in 2 months or albumin< 2.5
History of:
Cardiogenic shock
Ventricular or supraventricular arrhythmia
Cardiac arrest
Cardiopulmonary resuscitation or
Mechanical ventilation
Systolic blood pressure < 110
Creatinine > 2 or BUN > 40
Sodium < 135
Cardiovascular disease:
Ischemic cerebrovascular disease or
Peripheral vascular disease
Other comorbid illness:
Diabetes Mellitus
Dementia
COPD
Cirrhosis
Cancer
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Dementia
Advanced dementia with dependency in all activities of daily living, bedbound status,
urinary and bowel incontinence, decreased ability to communicate verbally, AND admission to a
hospital or skilled nursing facility with one or more of the following:
BMI < 18.5, decreased oral intake, or significant weight loss
Presence of at least one pressure ulcer
Evidence of at least one comorbid illness
Male sex and age > 90
Placement of a feeding tube due to inability to eat or history of aspiration
Geriatric Failure-to-Thrive
Age > 75, albumin < 3.5, dependency in 2 or more activities of daily living, AND
admission to a hospital or skilled nursing facility with one or more of the following:
Dependency in all activities of daily living with malnutrition
(weight loss >10% or albumin < 3)
Evidence of heart failure
Creatinine > 3
Evidence of delirium during hospitalization

End-Stage Renal Disease (ESRD)
ESRD on dialysis with age > 70 and 2 or more of the following:
KPS < 50
Significant comorbid condition such as
Coronary artery disease
Peripheral vascular disease
Heart failure
Cancer
Malnutrition
BMI < 19.5 or albumin < 2.2
Residence in a skilled nursing facility
Admission to an intensive care unit for an acute illness
Hip fracture with inability to ambulate
ESRD without dialysis with age > 70 and 1 or more of the following:
Dialysis withheld due to decreased performance status and significant
comorbidity
Dialysis withdrawn due to advanced age, functional dependence, and
comorbidity
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Cirrhosis
Decompensated hepatic cirrhosis and 1 or more of the following:
Child-Pugh 12 or greater
MELD 21 or greater
Decompensated hepatic cirrhosis with hospitalization for an acute illness related to liver disease
and 1 or more of the following:
Child-Pugh 10 or greater
MELD 18 or greater
Child-Pugh 9 or greater AND dependency in 3 or more ADL AND
malnutrition (significant weight loss and albumin < 2.5
Hospitalization in an intensive care unit related to severe decompensation of
liver disease, with hypotension requiring the use of vasopressors,
creatinine > 1.5, OR evidence of jaundice
Evidence of hepatopulmonary syndrome or rapidly progressive hepatorenal
syndrome

Chronic Obstructive Pulmonary Disease (COPD)
Hospitalization for a severe COPD exacerbation with hypoxemia (paO2 < 55),
hypercapnia (pCO2 > 50), dependence on supplemental O2, and 3 or more of the following:
Age > 70
Evidence of cor pulmonale
Repeat hospitalization within 2 months
History of intubation/mechanical ventilation
KPS < 60
Need for home care after discharge
Malnutrition (weight loss > 2.3 kg, albumin < 2.5, or BMI < 18
Creatinine > 2
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PCN Chronic Obstructive Pulmonary Disease (COPD-CODEX)
Mortality Prediction at 3 months and 1 year
Comorbidity :

Charlson Index
0-4
0 points
5-7
1 point
8 or greater
2 points
Obstruction: FEV1%
65 or greater
0 points
50-64
1 point
36-49
2 points
35 or less
3 points
Dyspnea:
mMRC = modified medical research council dyspnea scale
0-1
0 points
2
1 point
3
2 points
4
3 points
EXacerbation: exacerbations during the previous year (requiring ED visit and/or hospitalization)
0
0 points
1-2
1 point
3 or more
2 points
Score 1-10

Score
0
1
2
3
4
5
6
7
8
9
10

Predicted 3 month mortality (%)
0
0
0
2
5
5
8
10
15
18
20

Predicted 1 year mortality (%)
0
2
5
10
15
18
20
25
30
35
50

PCN Chronic Obstructive Pulmonary Disease (COPD-BODE)
Mortality Prediction at 4 years
Variable

BODE Index points

Body Mass Index (BMI)
More than 21
21 or less
Obstruction
FEV1% - 65 or greater
FEV1% 50-64
FEV1% 36-49
FEV1% 35 or less
Dyspnea
mMRC 0-1
mMRC 2
mMRC 3
mMRC 4
Exercise
6-minute Walk Test (meters)
350 or more
250-349
150-249
149 or less
Score 1-10

Approximate 4-year mortality (%)
BODE Score

4-year mortality (%)

0-2
3-4
5-6
7-10

20
33
43
82

0
1
0
1
2
3
0
1
2
3
0
1
2
3
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Prognostic Index: Liver Disease

Child-Pugh Score
Class A
Class B
Class C

5-6 points
7-9 points
10-15 points

Variable

Points

Serum bilirubin
<2
2-3
>3

1
2
3

3.5 or greater
3-3.5
Less than 3

1
2
3

Prothrombin time (INR)
Less than 1.7
1.7-2.3
2.3 or greater

1
2
3

Serum albumin

Ascites
None
Slight
Moderate

1
2
3

None
Minimal
Advanced

1
2
3

Encephalopathy
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PCN Heart Failure Risk Scoring System (HFRSS)

Disease-Specific, Non-Cancer Heart Failure
Community and Teaching Hospitals within 24 hours of admission (excludes > 105 years old and
non-residents)
Survival/Mortality Prediction at 30 days and 1-year
Start with age in years as initial score:
Respiratory Rate
Systolic BP
180 or more
160-179
140-159
120-139
100-119
90-99
Less than 90
Blood Urea Nitrogen (max 60 mg/dl)
Serum Sodium less than 136 meq/l
Cerebrovascular Disease
Dementia
Chronic Obstructive Pulmonary Disease
Cirrhosis
Cancer
Hemoglobin less than 10 g/dl

30 day
1-year
+ rate (breaths/min) + rate (breaths/min)
- 60
- 55
- 50
- 45
- 40
- 35
- 30
+ level in mg/dl
+ 10
+ 10
+ 20
+ 10
+ 25
+ 15
NA

- 50
- 45
- 40
- 35
- 30
- 25
- 20
+ level in mg/dl
+ 10
+ 10
+ 15
+ 10
+ 35
+ 15
+ 10

Risk Category

HFRSS Score

30 day mortality (%)

1-year mortality (%)

Very Low
Low
Intermediate
High
Very High

less than 60
61-90
91-120
121-150
more than 150

0.5
3-4
12-15
30
50-60

5-8
12-15
30
55-60
75
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Prognosis Assessment: PLAN Clinical Prediction Rule
Population:
hospital admission acute ischemic stroke without thrombolysis
Variable
Preadmission medical comorbidities

Points

ADL dependence
Cancer
CHF
Atrial Fibrillation

1.5
1.5
1.0
1.0

Level of consciousness
Reduced

5.0

Age

One point per decade (max = 10)

Neurologic deficit
Arm weakness
2.0
Leg weakness
2.0
Neglect or aphasia
1.0
______________________________________________________________________________
Correlation of PLAN Score to
30 day and
1 year
m-R* of 5 or 6 ( %)
mortality %
Less than 6
6
7
8
9
10
11
12
13
14
15
16
17
18
19
More than 19
*= modified Rankin score

0.7
1.9
1.4
2.1
4.4
4.4
7.6
10.9
15.3
21.7
29.3
35.4
42.5
50.5
61.2
65.9

2.1
4.8
4.5
6.4
13.1
16.2
21.7
26.3
32.0
42.2
46.0
57.7
63.3
74.3
73.8
83.6

0.9
1.2
1.3
2.5
4.3
6.0
9.8
14.8
20.3
30.7
35.8
43.9
54.4
65.0
73.2
78.4

PCN Prognosis Assessment Prolonged Mechanical Ventilation (ProVent score)
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Mortality Prediction at 3 months and 1 year for patients receiving prolonged mechanical ventilation –
measured on day #21 of mechanical ventilation
One (1) point each for:
Age 50 years or more
Vasopressor
Platelet count 150,000 or less
Hemodialysis or CRRT

Score
0
1
2
3
4

Observed 3 month mortality (%)
12
29
77
91
95

Observed 1 year mortality (%)
15
42
88
95
100

PCN Intracranial Hemorrhage (ICH Score)

Components

Points

Glasgow Coma Scale (GCS)
3-4
5-12
13-15
ICH volume, cm3
30 or more
Less than 30
Intra-ventricular hemorrhage
Yes
No
Infra-tentorial origin
Yes
No
Age, years
80 or more
Less than 80

2
1
0
1
0
1
0
1
0
1
0

Score 0-6

30-day mortality (%) correlated with ICH score:
Score
0
1
2
3
4
5
6

30-day Mortality (%)
0
10
25
75
95
99
100
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PCN Survival Postresuscitation – In-Hospital Cardiac Arrest (CASPRI)
Predictor
Age, years
59 or less
60-69
70-79
80 or older
Initial Rhythm VF/VT
Time to initial defibrillation
3 minutes or less
4-5 minutes
5 minutes or more
Initial Rhythm PEA
Initial Rhythm Asystole
Prearrest CPC score
1
2
3 or more
Location of arrest
Telemetry unit
Intensive Care Unit
Non-monitored unit
Duration of Resuscitation (minutes)
4 or less
5-9
10-14
15-19
20-24
25-29
30 or more
Factors present prior to arrest
Mechanical ventilation
Renal insufficiency
Hepatic insufficiency
Sepsis
Cancer
Hypotension
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Points
0
1
2
4

0
2
3
6
7
0
2
9
0
1
3
0
3
5
6
6
6
8
3
2
4
3
4
3

Predictor Points correlated with likelihood (mean survival %) of survival to hospital discharge
0-4
82.6
20-24 12.3
5-9
66.6
25-29 5.2
35 points or more = 0% survival to discharge
10-14 42.0
30-34 2.1
15-19 23.1
>34

PCN Cerebral Performance Category after Resuscitation Attempt (GO-FAR)
GO-FAR:

Good Outcome Following Attempted Resuscitation

Variable

GO-FAR Score

Neurologically intact or with minimal deficits at admission

- 15

Major trauma
Acute stroke
Metastatic or hematologic cancer
Documented bloodstream infection
Medical noncardiac diagnosis
Hepatic insufficiency
Bilirubin >2 mg/dl
AST > 2x normal
Cirrhosis
Admit from skilled nursing facility
Hypotension or hypoperfusion
Mean BP < 60
Vasopressor
IABP
Renal insufficiency or dialysis/CRRT
Serum creatinine > 2 mg/dl
Respiratory insufficiency
Intubation/mechanical ventilation
NIPPV
PaO2/FiO2 < 300
PaCO2 > 50 mmHg
PaO2 < 60
Pneumonia
Age
70-74
75-79
80-84
85 or older

10
8
7
7
7
6

6
5

4
4

1
2
5
6
11

GO-FAR Score correlated with % of survivors with CPC of 1 (chances for “good outcome”)
24 or more
0.8
(very low – less than 1%)
14-23
2.0
(low – 1-3%)
-5 to 13
9.2
(average – 3 -15%)
-15 to -6
27.8 (above average – more than 15%)
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PCN Hospice Diagnosis/Category Criteria Examples
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General End-Stage Disease Guidelines

Changes in clinical variables apply to patients whose decline is not considered reversible
Documented decline in functional status (both should be met)
1. Assistance needed with at least 2 ADLs (toilet, feed, dress, groom, walk, bathe)
2. Decline in PPS to less than 70%
Decline in nutritional status
Unintentional progressive weight loss (10% over 6 months)
Serum albumin < 2.5 gm/dl
Dysphagia leading to recurrent aspiration and/or inadequate intake
Increased ED visits, physician visits, or hospitalizations related to primary hospice diagnosis
Multiple co-morbidities
Goal for palliative care

Adult “failure to thrive”
PPS < 50%
BMI < 22
Declining enteral or parenteral nutrition support or has not responded to such nutritional
support, despite adequate caloric intake

PCN Hospice Diagnosis/Category Criteria Examples
Dementia

The patient has dementia which has progressed to:
FAST stage 7 or beyond
Unable to ambulate without assistance
Unable to dress without assistance
Unable to bathe without assistance
Urinary and fecal incontinence, intermittent or constant
No meaningful verbal communication
Stereotypical phrases only
Ability to speak is limited to six or fewer intelligible words
AND
The patient must have had one of the following within the past 12 months
Aspiration pneumonia
Pyelonephritis or other upper urinary tract infection
Septic episode
Decubitus ulcers, multiple, stage 3-4
Fever, recurrent after antibiotics
Inability to maintain sufficient fluid and calorie intake
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PCN Hospice Diagnosis/Category Criteria Examples
Liver Disease

The patient has end-stage liver disease demonstrated by:
Prothrombin time >5 sec – OR - INR > 1.5 – AND - serum albumin < 2.5 gm/dl
AND:
One or more of the following:
Refractory ascites
History of SBP
Hepatorenal syndrome
Refractory hepatic encephalopathy
History of recurrent variceal bleeding
Additional supporting documentation:
Progressive malnutrition
Muscle wasting with reduced strength and endurance
Continued active alcoholism (>80 gm alcohol/day)
Hepatocellular carcinoma
Hepatitis B positivity
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PCN Hospice Diagnosis/Category Criteria Examples
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Neurologic Disease
ALS
Parkinsons
Muscular Dystrophy
Myasthenia Gravis
Multiple Sclerosis
Neuromuscular Disease
Meet at least one of the following criteria:
1. Critically impaired breathing capacity – all of following:
a. Dyspnea at rest
b. Vital capacity < 30%
c. Requires oxygen at rest
d. Declines mechanical ventilation
2. Rapid disease progression:
a. Independent ambulation to wheelchair or bed-bound status
b. Normal to barely intelligible or unintelligible speech
c. Normal to pureed diet
d. Independence in most ADLs to needing major assistance in all ADLs
AND
Critical nutritional impairment – all of the following in the last 12 months:
a. Oral intake of nutrients and fluids insufficient to sustain life
b. Continuing weight loss
c. Dehydration or hypovolemia
d. Absence of artificial feeding methods
3. Rapid disease progression:
a. Independent ambulation to wheelchair or bed-bound status
b. Normal to barely intelligible or unintelligible speech
c. Normal to pureed diet
d. Independence in most ADLs to needing major assistance in all ADLs
AND
Life threatening complications – one or more of the following in the last 12 months:
a. Recurrent aspiration pneumonia
b. Pyelonephritis
c. Sepsis or recurrent fever
d. Stage 3 or 4 decubitus ulcer(s)

PCN Hospice Diagnosis/Category Criteria Examples
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Heart Disease/Cardiovascular
The patient has 1 and either 2 or 3:
1. CHF with NYHA class IV symptoms and both:
a. Significant symptoms at rest
b. Inability to carry out even minimal physical activity without dyspnea or angina
2. Patient is optimally treated with diuretics and vasodilators including ACEI
3. The patient has angina pectoris at rest, resistant to medical therapy, and is either not a
candidate for/or has declined invasive procedures.
Supporting documentation:
EF < 20%
Treatment resistant dysrhythmias
Cardiac-related syncope
Stroke related to cardiac embolism
History of CPR
Concomitant HIV

PCN Hospice Diagnosis/Category Criteria Examples

HIV/AIDS

The patient has either 1A or 1B; AND 2 AND 3

1A.

CD4+ < 25

1B.

viral load > 100,000

2.

At least one of the following:
CNS lymphoma
Untreated or refractory wasting (loss of > 33% lean body mass)
MAC bacteremia
PML
Systemic lymphoma
Visceral KS
Renal failure, no HD
Cryptosporidium infection
Refractory toxoplasmosis

3.

PPS < 50%
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PCN Hospice Diagnosis/Category Criteria Examples
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Pulmonary Disease
The patient has:
Disabling dyspnea at rest or with minimal exertion and little or no response to bronchodilators, resulting
in decreased functional capacity, fatigue, cough, AND
Progression of end-stage pulmonary disease, as evidenced by prior increasing visits to the emergency
department or prior hospitalizations for pulmonary infections and/or respiratory failure, AND
Room air findings of hypoxemia, as evidenced by pO2 < 55 mmHg and oxygen saturation < 88% or
hypercapnia as evidenced by pCO2 > 50 mmHg
Cor pulmonale and right heart failure secondary to pulmonary disease (not secondary to left heart
disease or valvulopathy)
Unintentional progressive weight loss greater than 10% of body weight over the preceding six months
Resting tachycardia > 100 bpm

PCN Hospice Diagnosis/Category Criteria Examples
Renal Failure

A patient has:
Acute renal failure OR
Chronic renal failure (ESRD) AND
The patient is not undergoing dialysis AND
Creatinine clearance < 10 cc/min OR
Serum creatinine > 8 mg/dl (6 for diabetics)
Supporting documentation:
Mechanical ventilation
Malignancy
Chronic lung disease
Advanced cardiac disease
Advanced liver disease
Sepsis
Immunosuppression/AIDS
Albumin < 3.5 gm/dl
Cachexia
Platelet count < 25,000
Disseminated Intravascular Coagulation (DIC)
Gastrointestinal bleeding
Uremia
Oliguria (<400 cc/day)
Intractable hyperkalemia (>7.0) not responsive to treatment
Uremic pericarditis
Hepatorenal syndrome
Intractable fluid overload
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PCN Hospice Diagnosis/Category Criteria Examples
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Stroke and Coma
Acute hemorrhagic or ischemic stroke
Poor functional status (PPS < 50 %) AND
Poor nutritional status with inability to maintain sufficient fluid and calorie intake as evidenced by one
or more of the following:
10% or more weight loss in past 6 months
7.5% or more weight loss in past 3 months
Serum albumin < 2.5 gm/dl
Current history of pulmonary aspiration without effective response
to speech therapy interventions to improve dysphagia
and decrease aspiration events

Supporting documentation:
Coma or persistent vegetative state secondary to stroke, beyond 3 days duration
Coma or severe obtundation, secondary to post-anoxic stroke
accompanied by severe myoclonus, persisting beyond 3 days after the anoxic event
Chronic phase of hemorrhagic or ischemic stroke evidenced by:
Post stroke dementia, FAST stage 7 or beyond
Poor functional status with KPS %0% or less
Coma (any etiology) with any 3 of the following on day three of coma:
Abnormal brainstem response
Absent verbal response
Absent withdrawal response to pain
Serum creatinine > 1.5 mg/dl

PCN Hospice Diagnosis/Category Criteria Examples
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Cancer
Clinical findings of malignancy with widespread, aggressive, or progressive disease
as evidenced by increasing symptoms, worsening lab values, and/or evidence of metastatic
disease
AND
PPS 70 % or less
AND
Refuses further life-prolonging therapy or continues to decline in spite of definitive therapy
(may receive disease-specific intervention if palliative)

The following cancer disease categories are considered hospice appropriate due to the small probability
that treatment would result in cure or cessation of disease:
Category 3:
malignancies that are treatable but incurable when metastatic in a large percentage of
patients, with favorable prognosis:
prostate, breast, CLL, CML, NHL, multiple myeloma, myelodysplastic syndrome
(often may be controlled for periods of time with hormonal and/or chemotherapy, may require
no therapy or are only treated when symptoms occur, generally have a history of having
received and failed one or more standard therapeutic regimens and should have symptoms
compatible with disease progression before considering hospice option)
Category 4:
malignancies that are treatable in only a small percentage of patients with less favorable
prognosis:
invasive bladder, glioblastoma, gynecological carcinomas other than ovary, colorectal, gastric,
head and neck, esophageal, NSCLC, soft tissue sarcoma
(majority are adult solid tumors, presence of metastatic disease generally indicative of a
terminal prognosis, usually 40% or less of patients have an objective response to chemotherapy,
chemotherapy responses are usually not durable, impact of chemotherapy on symptoms and
quality of life not well documented in medical literature, as chemotherapy is of limited benefit
to most patients once these diseases have metastasized such patients could be offered the
option of hospice in lieu of chemotherapy, if chemotherapy is chosen by the patient as a
therapeutic option, failure of first-line therapy should prompt serious consideration of hospice)
Category 5
malignancies that are virtually untreatable:
renal cell, pancreatic, malignant melanoma
(generally resistant to currently available chemotherapy, with the lack of efficacious systemic
therapy – patients with these diseases and have metastatic disease should be offered hospice
As an option)

Syndrome of Imminent Death

Early
Bed-bound
Loss of interest
Loss of ability to eat/drink
Increased time sleeping
+/- delirium
Middle
Obtunded
Oral secretions (“rattle”)
Late
Coma
Fever
Aspiration
Altered respiratory pattern
Mottling
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PCN EOL Management Palliative Sedation
Confirm that goal of care is comfort
Advanced terminal illness
Suffering severe refractory physical or neuropsychiatric symptoms – or – psychosocial problems
Order to withhold life-sustaining interventions
Informed consent
Document all of above, inform clinical team
Specify loading dose, infusion, bolus doses
Midazolam
0.3-0.5 mg/kg over 2-5 minutes
Infusion 0.02-0.1 mg/kg/hr
Additional boluses = hourly infusion rate
Propofol
(central venous catheter only)
Start infusion 2.5-5.0 mcg/kg/min (10-20 mg/hr)
Bolus doses 10-20 mg q 10 min
Pentobarbital
Loading dose 2-3 mg/kg
Infusion 1-2 mg/kg/hr
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PCN SQ Dosing

Drug

Bolus(mg)

Infusion(mg)

Morphine Sulfate
Hydromorphone
Fentanyl
Midazolam
Haloperidol
Phenobarbital
Metoclopramide
Hyoscine
Glycopyrrolate
Octreotide

2.5-5 q 4h
2-5 q 4h
use infusion
2.5 q 4h
0.5-2.5 q 6-8 h
60 q 6-8 h
10 q 6 h
0.3-0.6 q 2-4 h
0.2-0.4 q 4-6 h
0.1-0.2 q 8 h

15-30/24 h
15/24 h
0.150-0.300/24 h
20-40/24 h
5-25/24 h
200-1000/24 h
30-100/24 h
0.6-2.4/24 h
0.6-1.2/24 h
0.3-0.6/24 h
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DNAR
Patient Categories/Hierarchy of Decision-makers
DNAR: Do-Not-Attempt-Resuscitation
Basically healthy
20-40% survival
+ benefit
Advanced/Chronic Illness
5-20% survival
+/- benefit
Imminent death
0%
0 benefit
Hierarchy of decision-makers:
Capable patient
DPOAHC
Legal guardian
Spouse
Adult children
Parents
Adult sibling(s)
Grand-parents
Other

Pain Management Guidelines (NCCN)
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1.

Use a multidrug approach. Combine opioids with nonopioids and adjuvant
medications.

2.

Base administration schedule on the analgesic’s duration of effect. Best to use
sustained-release opioids for scheduled dosing and immediate-release opioids for
rescue or breakthrough dosing.
In opioid-naïve patients, start with low-dose, short-acting opioids and titrate for
effect.

3.
4.

Avoid meperidine (Demerol), propoxyphene (Darvon), and the mixed agonistantagonist opioids (eg, Stadol, Nubain, Talwin). Do not exceed 4000 mg of
acetaminophen (APAP) in 24 hours.

5.

Noninvasive routes preferred. For severe pain or rapidly escalating pain, it may be
necessary to provide IV analgesics until the pain is managed. If oral or transdermal
dosing is no longer practical or appropriate, continuous subQ or IV infusions are
indicated.

6.

Mild pain (rating 1-3): Start with simple analgesics, APAP or NSAIDS, with adjuvant
analgesics as appropriate.

7.

Moderate to severe pain (rating 4-10): When pain does not respond to nonopioid
analgesics and adjuvants, consider adding an opioid. Drugs with APAP, ASA, or
NSAIDS in combination with opioids limit flexibility of dosing.

8.

Titration: Increase by 25% to 50% for moderate pain; increase by 50% to 100% for
severe pain. Or calculate the average dose of breakthrough medication per day and
add to the sustained-release medication dose (except when breakthrough is taken
for incident pain).

9.

Breakthrough: Scheduled dosing will maintain stable serum drug levels and provide
consistent relief. Patients receiving long-acting opioids or continuous parenteral
infusions must have an order for breakthrough pain medication. Frequent
breakthrough dosing requires a change in the sustained-release drug dose. Oral
breakthrough dose is 10% to 20% of the oral 24-hour baseline dose. Peak effect of
immediate-release opioid is ~ 1 hour; may repeat dose every hour if patient is not
sedated. IV/SQ breakthrough dose is 50% to 100% of the hourly IV/SQ rate. Peak
effect of IV opioids is 10-15 minutes; may repeat dose every 15 minutes if patient
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10.

not sedated. Peak effect of SQ opioids is 30 minutes; may repeat dose every 30
minutes if patient not sedated. Intramuscular dosing not recommended.

11.

When changing drug or route of administration, use equianalgesic doses. If
changing from one drug to another, the new drug may be more effective because of
differences of potency or drug availability. Start at 2/3 to 3/4 of the amount
calculated by using equianalgesic tables. Make sure breakthrough medication is
available and titrate dose according to individual response.

Manage opioid adverse effects. Patients never become tolerant to the constipating effects of
opioids. Always start stimulant laxative/softener combination with opioids
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Equianalgesic Opioid Conversion (Miscellaneous)
Morphine Sulfate (MS) 30 mg PO = 10 mg IV
(3:1)
Hydromorphone (HM) 7.5 mg PO = 1.5 mg IV (5:1)
Oxycodone (OX) 0.66 mg PO = MS 1 mg PO
Fentanyl (FT) 1 mcg/hr = 2 mg Oral Morphine Equivalent (OME)
Codeine 30 mg PO = MS 4.5 mg PO
Tramadol 50 mg PO = MS 10 mg PO
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Converting Opioids: Point A to Point B
M=morphine, H=hydromorphone, X=oxycodone, F=fentanyl, MET=methadone
O=oral, V=intravenous, T=transdermal
1: all doses in mg unless otherwise noted
2: note 100 mcg = 0.1 mg
3. dose in mcg/hr

B:
→DESIRED1→

MO

MV

HO

HV

---

1/3

1/4

1/20 2/3

(“OME”)

XO

FV2

FT3

(MCG/HR)

METO

METV

A:↓CURRENT ↓
1

MO
(“OME”)

1/300 1/2

¼
OME/24°< 90
1/8
OME/24°90300
1/12
OME/24°>300

MV
3/1
--3/4 1/7 2/1
1/100 3/2
HO
4/1
4/3
--1/5 3/1
1/75 2/1
HV
20/1
7/1
5/1
--14/1 1/15 10/1
XO
3/2
1/2
1/3 1/14 --1/200 3/4
FV
300/1 100/1 75/1 15/1 200/1
--150/1
FT3 (MCG/HR)
2/1
2/3
1/2 1/10 4/3
1/150 --METO
5/1
--METV
13.5/1
1.3/1
A:
Find current drug (Point A) in far left column
B:
Find desired drug (Point B) in top row
Intersection of A and B in table defines conversion ratio
Dose desired drug (B) = Dose current drug (A) x conversion ratio

1/2
---

Calculated dose represents an estimated equianalgesic dose. Significant individual patient
variation should be expected. The actual dose of the desired drug to administer should be
adjusted for a variety of factors including but not limited to: age, pain intensity, cross-tolerance,
and renal/hepatic dysfunction.
Consider the following when adjusting the calculated (estimated) equianalgesic dose:
0% reduction:

moderate to severe pain, no side effects (sedation,
respiratory depression, neurotoxicity) on current
medication
25% reduction:
mild to moderate pain, no side effects
50% reduction:
mild or controlled pain, presence of side effects

PCN Guidelines for Opioid Rotation
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Select the new drug on the basis of pharmacologic features, previous experience, availability, cost
Calculate the equianalgesic dose:
If switching to any opioid other than methadone of fentanyl:
Plan dose reduction of 25-50% (incomplete cross tolerance)
Select dose reduction closer to 50% if higher dose, elderly, medically frail
If switching to methadone:
Dose reduction is 50-75%, rarely converting to methadone at dose higher than 100 mg/day
If switching to transdermal fentanyl:
Use calculated equianalgesic dose included in product information (approx. OME/2)
On the basis of assessment of severity of pain severity and other medical/psychologic characteristics, increase or
decrease the calculated dose by 15-30% to increase the likelihood that the initial dose will be effective, or
conversely, unlikely to cause withdrawal or side-effects
If a supplemental (breakthrough) dose is used, calculate this dose at 10-20% of the total daily dose (OME) and
administer at an appropriate interval
Exception: transmucosal fentanyl formulations should always be initiated at lower doses and titrated
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PCN Opioid Analgesics and Organ System Dysfunction

System Failure

Preferred

Consider

Avoid

Hepatic

hydromorphone
methadone
morphine

oxycodone

fentanyl
hydrocodone
tramadol

Renal

methadone
fentanyl
oxycodone

hydromorphone
hydrocodone

morphine
codeine
tramadol

Hepatic + Renal

methadone
hydromorphone

fentanyl
oxycodone

morphine
codeine
tramadol
hydrocodone

PCN Opioid Dose Size Availability
Morphine IR
Morphine SR
Oxycodone IR

15, 30
Oral solution 1mg/ml, 2mg/ml, 4mg/ml, 20mg/ml
15, 30, 60, 100

Oxycodone SR

5, 15, 30
Oral solution 1mg/ml, 20mg/ml
10, 15, 20, 30, 40, 60, 80

Hydromorphone

2,4,8 po tablets

Fentanyl

lozenge – 2000, 400,600, 800, 1200, 1600 mcg
buccal – 100, 200, 400, 600 800 mcg
transdermal – 12, 25, 50, 75 mcg/hr

Methadone

5, 10
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Opioid Risk Variables
Family History
Alcohol, Illegal Drugs, Prescription agents
Personal History
Alcohol, Illegal Drugs, Prescription agents
Age (16-45)
History preadolescent sexual abuse
Psychologic/Psychiatric Disease:
ADD, OCD, Bipolar, Schizophrenia, Depression

Aberrant Behaviors – more predictive:
Selling prescription drugs
Prescription forgery
Stealing/”borrowing”
Injecting oral drugs
Multiple drugs
Unsanctioned escalation
Resisting change despite side effects
Prescription losses
Aberrant Behaviors – less predictive:
Aggressive complaining about need for increased doses
Drug hoarding
Specific drug request
Use of drug to treat other symptoms
Multiple escalations

127

PCN Urine Drug Testing
Drug:

Metabolite(s):

Duration (days):

Codeine
Morphine
Hydrocodone
Hydromorphone
Oxycodone
Oxymorphone

codeine, morphine, hydrocodone
morphine, hydromorphone, codeine
hydrocodone, hydromorphone
hydromorphone
oxycodone, oxymorphone, hydrocodone
oxymorphone, oxycodone

2-4
2-4
2-4
2-4
2-4
2-4

Alprazolam
Clonazepam
Chlordiazepoxide
Diazepam
Flurazepam
Lorazepam
Oxazepam
Temazepam

alprazolam, alpha-hydroxyalprazolam
7-aminoclonazepam
nordiazepam, oxazepam
nordiazepam, temazepam, oxazepam
2-hydroxyethyl flurazepam
lorazepam
oxazepam
oxazepam

up to 7
up to 7
up to 7
up to 7
up to 7
up to 7
up to 7
up to 7

Barbituates
Cocaine
Alcohol
THC
PCP

up to 6
2-4
0.25-0.5
up to 5
2-7

Opioids
Methadone
Propoxyphene
Tramadol

2-4
2-4
2-4
2-4
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PCN Methadone Notes
Convert PO Methadone to IV Methadone:
Infused over 24 hrs or divided q6-8 hr

Total Methadone Dose/2

Convert 24 hour Oral Morphine Equivalent (OME) to equianalgesic Morphine dose:
OME
Ratio OME to 24 hr PO Methadone dose
<60
“opioid naïve” – Methadone 2.5 mg bid or tid
60-200
10:1 (less than 65 years old)
>200
20:1 (or if greater than 65 years old)
(consider Fixed dose Methadone of 30 mg when OME > 300)
Adjust (decrease) calculated dose of Methadone up to 50%:
Incomplete cross tolerance
Varied metabolism
Imperfection of equianalgesic tables
Dose should not be increased before 5-7 days and not increased by more than 5-10 mg/day once a total
daily dose of 30-40 mg has been reached
ECG evaluation for QTc prolongation based on clinical judgment
Methadone Interactions
CYP450 inhibition > increase effect
Macrolides – clarithromycin, erythromycin
diltiazem, verapamil
ketoconazole
itraconazole
cyclosporine
grapefruit juice
CYP450 induction > decrease effect
phenobarbital
phenytoin
carbamazepine
ritonavir

Estimate of Methadone to Morphine Conversion (JPM 2008;11:1103)
1 mg Methadone PO =
4.7 mg Morphine PO
1 mg Methadone IV
=
13.5 mg Morphine PO
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PCN Methadone Notes 2

This table incorporates:
Incomplete cross tolerance
Variations in metabolism
Imperfections in equianalgesic tables
Ø Do not decrease after conversion

OME mg/24 hrs

Morphine to Methadone Ratio

Less than 100
101-300
301-600
601-800
801-1000
Greater than 1000

Oral methadone to IV methadone = 2:1

3:1
5:1
10:1
12:1
15:1
20:1
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PCN Fentanyl (F) Notes
For bolus dosing:
100 mcg (0.1 mg) F = 10 mg Morphine IV = 30 mg Morphine PO
For continuous infusion: 100 mcg (0.1 mg) F/hr = 6.6 mg Morphine/hr
F TTD to F IV:
F IV to F TTD:
OME to F TTD:

decrease by 50%
1:1
OME/2

F IV peak effect 6-10 min, duration 30-90 min
F TTD doses available:

mcg/hr 12, 25, 50, 75, 100

F oral lozenge (Actiq) = OTFC
200 mcg OTFC =

12 mg Morphine PO
2-4 mg Morphine IV
7.5 mg oxycodone PO

OTFC mcg doses sizes available:

200, 400, 600, 800, 1200, 1600

F buccal tablets (Fentora):
dose sizes available:

2X strength of OTFC
100, 200, 400, 600, 800
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PCN Fentanyl Notes 2
50 mcg/hr Fentanyl TD = OME 100
IV Fentanyl
Peak effect IV push = 6-10 minutes
Duration of effect = 30-90 minutes
Conversion to IV Fentanyl:
100 mcg IV Fentanyl = 10 mg IV Morphine
(for bolus dosing or do not decrease for cross tolerance)
100 mcg Fentanyl IV = 6.6 mg Morphine Sulfate
(for continuous infusion)
TransDermal to IV Fentanyl - decrease by 50%
IV to TD - 1:1

132

PCN Aberrant Behavior Risk

Family History EtOH
Family History Illegal Drugs
Family History Prescription Drugs
Personal History EtOH
Personal History Illegal Drugs
Personal History Prescription Drugs
Age 16-45
History Preadolescent Sexual Abuse
Psychological Disease
ADD
OCD
Bipolar
Depression

Low Risk 0-3 Moderate Risk 4-7

Female Score
1
2
4
3
4
5
1
3
2
2
2
1
__________

Male Score
3
3
4
3
4
5
1
0
2
2
2
1
____________

High Risk 8 or more

Psychological Variables Potentially Implicated in Opioid-Related Mortality
Fear and desperation in the face of pain (catastrophizing)
Impulsivity
Chemical coping
Lack of acceptance
Personal disorder (“borderline”)
A:
odd, eccentric
B:
emotional overreactivity, self destructiveness, repetitive acting out
C:
anxious, avoidant
Demoralization, existential distress
Sensation seeking
Escapism

Categories of Interventions for Cancer Pain
Pharmacological

Interventional

Rehabilitative

Psychological

Neurostimulation

Opioid analgesics
Non-opioid analgesics
Adjuvant analgesics
Injection therapies
Neural blockade
Implant therapy
Modalities
Therapeutic exercise
Occupational therapy
Hydrotherapy
Psychoeducational interventions
Cognitive-behavioral therapy
Relaxation therapy
Guided imagery
Other stress management and psychotherapy
Transcutaneous
Transcranial
Implanted

Integrative (complementary, alternative)
Acupuncture
Massage
Physical movement
Others
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Psychoactive Meds
SSRI:
Citalopram
Fluoxetine
Paroxetine
Sertraline

(Celexa)
(Prozac)
(Paxil)
(Zoloft)

mg dosage
20-80
20-80
20-80
50-300

Fewest drug/drug interactions: citalopram, sertraline
Sedation, discontinuation syndromes: paroxetine
SNRI:
Venlafaxine
Duloxetine

Atypical:
Bupropion
Mirtazapine

(Effexor)
37.5-300
(Cymbalta)
20-120
for neuropathic pain at least 60 mg qd

(Wellbutrin)
(Remeron)

100-450
15-45

seizure risk
increased appetite, weight gain

2nd generation Anti-Psychotic Agents:
Haloperidol
(Haldol)
Risperidone
(Risperdal)
Olanzapine
(Zyprexa)
Aripiprazole
(Abilify)
Quetiapine
(Seroquel)
Clozapine
(Clozaril)

2.5-15
1-6
2.5-30
5-30
25-800
250-450

Benzodiazepines:
Alprazolam
Clonazepam
Diazepam
Lorazepam

(Xanax)
(Klonopin)
(Valium)
(Ativan)

0.25-3
0.25-3
2.5-20
0.5-5

equivalent PO dose mg
0.5
0.25
5.0
1.0

Flurazepam
Temazepam

(Dalmane)
(Restoril)

15-30
10-20

30
20

GABAa – Sleep Agents:
Zaleplon
(Sonata)
Zolpidem
(Ambien)

5-10
5-10

Other:
Buspirone
Trazodone

(Buspar)

10-45
25-100

PCN Anti-Depressant Agents – Notes
Escitalopram
Citalopram
Fluoxetine
Paroxetine
Sertraline
Venlafaxine
Duloxetine
Desipramine
Nortriptyline
Mirtazapine
Bupropion

Methylphenidate

Citalopram

Mirtazapine

Fluoxetine
Bupropion
Duloxetine

5-20 qd
fewer interactions
10-40 qd
fewer interactions
5/10-60 qd
longer half-life, taper when discontinuing
10 qPM – 40
sedating, significant interactions
12.5/25-200
37.5 qAM or bid-150 bid
stimulating (not use with anxiety), taper
10/20 q AM -60 bid
use with coexistent anxiety
Nausea, dry mouth, constipation
10/25 qhs- 150/day
10 qhs – 150
fewer anti-cholinergic side effects
7.5/15 qhs-60
sedation, weight gain
NE, 5HT antagonist
75-100 qAM – 450/day useful with fatigue, low energy
not with seizures, bulimia, anorexia
weak NE, 5HT, Dop antagonist
2.5/5 qAM or noon
side effects: nervousness, agitation
- 60/day

reduces agitation, anxiety
Not as activating as fluoxetine
Not as sedating as paroxetine
“neutral
sedation, increased appetite, enhances effect of Coumadin
not effective for pain
consider with combination of nausea/anorexia/insomnia/depression
activating
activating
better tolerated in elderly
consider with depression/anxiety/neuropathic pain in elderly

Tri-cyclic agents:
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contraindicated with CHF, liver failure, BPH

136
PCN – Antidepressant Medication Considerations (CoMorbid Neuro/Med and Psych Symptoms)
Symptom(s)
Depression+
Anxiety
OCD
Psychosis
Somatization
Abulia
Delerium or Dementia
Fatigue
Insomnia
Pain
Parkinsonism
Seizures
Tremor
Stroke
Vertigo
Advanced Age
Constipation
Diarrhea
DM
Glaucoma
Heart Disease
Hypotension
Renal Failure
Hepatic Failure
Nausea, GERD
Overweight
Pregnancy
Sexual Dysfunction
Smoker
Urine Retention

Consider

SNRI
Fluoxetine
SSRI, SNRI + Anti-psych
Duloxetine
Bupropion
Citalopram
Bupropion, Fluoxetine
Mirtazapine
Duloxetine, TCA
Bupropion, Mirtazapine
SSRI, SNRI
Mirtazapine
Citalopram
Fluoxetine
Citalopram, Bupropion
Bupropion, SSRI, SNRI
Mirtazapine, TCA
Bupropion, SSRI, SNRI
Bupropion, SSRI, SNRI
SSRI
Bupropion, SNRI
Fluoxetine
Bupropion
Bupropion
SSRI, SNRI
Bupropion
Bupropion
Bupropion

(SSRI,SNRI,Bupropion,Mirtazapine)
-no agent superior for associated pain, anxiety, insomnia
-higher incidence of side effects:
Venlafaxine > nausea
Sertraline > diarrhea
Mirtazapine > weight gain
Bupropion > less sexual dysfunction
Mirtazapine > faster onset of action

Avoid

TCA, Bupropion
TCA, Bupropion
TCA
TCA, Paroxetine
TCA, Bupropion
TCA, Paroxetine
TCA, Fluoxetine
SSRI
Sertraline, Paroxetine
Bupropion
SSRI, SNRI
TCA
TCA
TCA
TCA
SSRI, Bupropion
TCA, Paroxetine
TCA
TCA, Mirtazapine
TCA
Bupropion
Duloxetine, Citalopram
Paroxetine, Sertraline
TCA, Mirtazapine
TCA
Paroxetine, SSRI
TCA
TCA
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Anti-Anxiety Agents – Notes

Alprazolam

0.25-2 tid/qid

peak 30 minutes, ++ rebound

Lorazepam

0.5-1.5 bid/qid

peak 5-20 min, ½ life 13-15 hrs

Clonazepam

0.25-2 bid/tid

peak 20-60 min, ½ life 19-50 hrs

Diazepam

2-10 bid/qid

peak 15-45 min, ½ life 20-50 hrs
metabolites 50-100 hrs

Buspirone

5-10 bid/tid

peak 1-1.5 hrs, ½ life 2-11 hrs

Haloperidol

0.5-5 q2-12 hrs
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NSAID Notes

NSAID Classes:
Propionic acids
Fenoprofen
Ibuprofen
Ketoprofen
Naproxen
Acetic acids
Diclofenac
Indomethacin
Ketorolac
Sulindac
Tolmentin
Endic acids
Meloxicam
Piroxicam
Anthranilic acids
Mefenamic acid

Risk for GI complications:
Prior ulcer, GI bleed
Age > 60
High dose
Concurrent steroids
Concurrent anticoagulation
1 or 2 variables:
More than 2 variables:

moderate risk, use cytoprotective agent concurrently
“don’t use”

Other contraindications:
Strong history CV disease
Hypercoagulable state
Renal disease/failure
Low perfusion state
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PCN Ketamine Notes

Sub-anesthetic (off-label) uses for pain management
MNDA channel blockade – involved in central (dorsal horn) sensitization
Consider for: neuropathic pain
opioid-induced hyperalgesia (opioid alternative)
Continuous IV infusion:
PO Ketamine:

0.05-0.3 mg/kg/hr

liquid – dilute to 50 mg/ml
start 10-25 mg tid to qid, titrate in steps of 10-25 mg
usual effective dose 100-300 mg/day

PCN Malignant Epidural Spinal Cord Compression (MESCC)

Surgery Indications:
Spinal instability
Previous RT
Worse despite RT
Radioresistant tumor
Unknown primary
Paraplegia less than 48 hrs
Single area of compression
Steroid dosing:

dexamethasone

“high dose” – if neuro exam abnormal
96 mg bolus IV, 24 q 6 hr po x 3 days
10 day taper
“moderate dose” – all others
10 mg bolus IV, 4 qid
2 week taper
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PCN:

Nausea/Vomiting
Nervous System Pathways/Mechanisms/Receptors
Correlation of Mechanisms/Receptors with Medications

4 pathways:

Chemoreceptor Trigger Zone
Cortex
Peripheral
Gastrointestinal (GI)
Serosa
Viscera
Vestibular

(CTZ)

Receptors:

Acetylcholine (Ach)/Muscarinic(m)
Dopamine-2 (D2)
Histamine (H1)
Neurokinin (NK)
5-hydroxytryptamine-2 (5-HT2)
5-hydroxytryptamine-3 (5-HT3)

CTZ, opiods > D2 >

metoclopramide, prochlorperazine, chlorpromethazine, haloperidol,
olanzapine

ChemoRx, RT, opioids, uremia, post-op > 5-HT3>
ondansetron, dexamethasone
Bowel obstruction > D2, Ach >
metoclopramide, haloperidol/olanzapine, dexamethasone, hyoscyamine
Motion > H1 >
Sample Agents:

scopolamine, diphenhydramine, promethazine

Metoclopramide
Prochlorperazine
Chlorpromazine
Promethazine
Diphenhydramine
Scopolamine
Hyoscyamine

D2 (GI), 5HT2
D2 (CTZ)
D2 (CTZ)
D2, H1, Ach
H1
Ach
Ach

Ondansetron
Mirtazapine

5HT3
5HT3

Olanzapine
Haloperidol
Propofol

D2, Ach, H1, 5HT3
D2
5HT3
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PCN NYHA Heart Failure Classification
Symptoms = fatigue, dyspnea, palpitations, angina
I:

cardiac disease without resulting limitation of physical activity
ordinary physical activity does not cause symptoms

II:

cardiac disease resulting in slight limitation of physical activity
comfortable at rest
ordinary physical activity results in symptoms

III:

cardiac disease with limitation of physical activity
comfortable at rest
less than ordinary physical activity causes symptoms

IV:

cardiac disease resulting in inability to carry out any physical activity
symptoms present even at rest
if any physical activity is undertaken, discomfort is increased

PCN LVAD Issues to consider

Device Failure/infection
Artificial nutrition/hydration
Transfusions
Renal replacement therapy
Mechanical ventilation
Organ donation
Comorbidities
Stroke
Sepsis
Renal failure
Catastrophic event
Peri-operative mortality/morbidity
Rehabilitation plans
Quality of life
Goals/expectations
Psychosocial assessment
Spiritual/religious preferences
Reference:

Swetz, LVAD Preparedness Plan
Mayo Clinic Proceedings
2011;86(6):493
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PCN SCCM Guidelines Pain/Agitation/Delerium
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Agitation in critically ill patients may result from inadequately treated pain, anxiety,
delirium, and/or ventilator dysynchrony.
Detection and treatment of pain, agitation, and delirium should be reassessed often in
these patients.
Patients should be awake and able to purposely follow commands in order to
participate in their care unless a clinical indication for deeper sedation exists.
Assess and Treat Statements and Recommendations
Pain assessment should be routinely performed in all ICU patients (1B).
Self report is preferred over the use of behavioral pain scales to assess pain in ICU patients who are
able to
communicate (B).
The BPS and CPOT are the most valid and reliable behavioral pain scales for use in ICU patients who
cannot communicate (B).
Vital signs should not be used alone to assess pain, but they may be used adjunctively for pain
assessments (2C).
Preemptively treat chest tube removal with either analgesics and/or non-pharmacologic therapy (1C).
Suggest preemptively treating other types of procedural pain with analgesic and/or non-pharmacologic
therapy (2C).
Use opioids as first line therapy for treatment of non-neuropathic pain (1C).
Suggest using non-opioid analgesics in conjunction with opioids to reduce opioid requirements and
opioid-related side effects (2C).
Use gabapentin or carbamazepine, in addition to intravenous opioids, for treatment of neuropathic pain
(1A).
Use thoracic epidural for postoperative analgesia in abdominal aortic surgery patients (1B).
Suggest thoracic epidural analgesia be used for patients with traumatic rib fractures (2B).
Depth and quality of sedation should be routinely assessed in all ICU patients (1B).
The RASS and SAS are the most valid and reliable scales for assessing quality and depth of sedation
in ICU patients (B).
Suggest using objective measures of brain function to adjunctively monitor sedation in patients
receiving neuromuscular blocking agents (2B).
Use EEG monitoring either to monitor non-convulsive seizure activity in ICU patients at risk for seizures,
or to titrate electrosuppressive medication to achieve burst suppression in ICU patients with elevated
intracranial pressure (1A).
Target the lightest possible level of sedation and/or use daily sedative interruption (1B).
Use sedation protocols and checklists to facilitate ICU sedation management (1B).
Suggest using analgesia-first sedation for intubated and mechanically ventilated ICU patients (2B).
Suggest using non-benzodiazepines for sedation (either propofol or dexmedetomidine) rather than
benzodiazepines (either midazolam or lorazepam) in mechanically ventilated adult ICU patients (2B).
Delirium assessment should be routinely performed in all ICU patients (1B).
The CAM-ICU and ICDSC delirium monitoring tools are the most valid and reliable scales to assess
delirium in ICU patients (A).
Mobilize ICU patients early when feasible to reduce the incidence and duration of delirium, and to
improve functional outcomes (1B).
Promote sleep in ICU patients by controlling light and noise, clustering patient care activities, and
decreasing stimuli at night (1C).
Avoid using rivastigmine to reduce the duration of delirium in ICU patients (1B).
Suggest avoiding the use of antipsychotics in patients who are at risk for torsades de pointes (2B).
Suggest not using benzodiazepines in ICU patients with delirium unrelated to ETOH/benzodiazepine
withdrawal (2B).
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PAIN 1. ICU patients routinely experience pain at rest and with ICU care (B). Pain in cardiac surgery145
patients, especially women, is poorly treated (B). Procedural pain is common in ICU patients (B).
2. Perform routine pain assessment in all patients (1B). In motor intact patients unable to self report, we
suggest using behavioral pain scales rather than vital signs to assess pain (2C). The BPS and CPOT are
the most valid and reliable behavioral pain scales (B). Vital signs should only be used as a cue for further
pain assessment (2C).
3. For non-neuropathic pain, use intravenous opioids as first line analgesic therapy (1C); use non-opioid
analgesics to reduce opioid side effects (1C); and use either gabapentin or carbamazepine in conjunction
with intravenous opioids for neuropathic pain (1A).
4. Suggest preemptively treating procedural pain (2C), especially chest tube removal (1C).
5. Use thoracic epidural analgesia for abdominal aortic surgery (1B), and suggest also using for traumatic
rib fractures (2B). No evidence guides the use of lumbar epidural analgesia for abdominal aneurysm
surgery (0A), or thoracic epidural analgesia for either intrathoracic or nonvascular abdominal surgical
procedures (0B). No evidence guides the use of regional vs. systemic analgesia in medical ICU patients
AGITATION 1. Maintaining lighter levels of sedation in ICU patients is associated with improved clinical
outcomes (B); light levels of sedation should be maintained in these patients (1B).
2. The RASS and SAS scales are most valid and reliable instruments for assessing adequacy and depth
of sedation (B).
3. Use Brain Function monitors only as adjuncts to subjective sedation scales in unparalyzed patients
(1B), but suggest using brain function monitors to primarily monitor depth of sedation in patients receiving
neuromuscular blocking agents (2B).
4. Use EEG monitoring to monitor non-convulsive seizure activity in ICU patients at risk for seizures, and
to titrate burst suppression therapy in ICU patients with elevated intracranial pressure (1A).
5. Use either use daily sedative interruption or titrate sedative medications to maintain light levels of
sedation (1B). Suggest using Analgesia-first sedation (2B). Suggest using non-benzodiazepines rather
than benzodiazepine infusions for sedation (2B). Use sedation protocols and daily checklists to integrate
and to facilitate management of pain, sedation, and delirium in ICU patients (1B).
1. Delirium is associated with increased mortality (A), prolonged ICU and hospital LOS (A), and post-ICU
cognitive impairment (B).
2. Delirium risk factors include: pre-existing dementia, HTN, history of alcoholism, and a high severity of
illness at baseline (B); coma (B); and benzodiazepine use (B). Mechanically ventilated ICU patients at risk
for delirium have a lower delirium prevalence when treated with dexmedetomidine rather than with
benzodiazepines (B).
3. Routinely monitor ICU patients for delirium (1B). The CAM-ICU and ICDSC are the most valid and
reliable instruments for this purpose (A).
4. Pursue early mobilization to reduce the incidence and duration of delirium (1B).
5. Suggest not using either haloperidol or atypical antipsychotics prophylactically to prevent delirium (2C).
6. Promote sleep in adult ICU patients by optimizing patients’ environments, using strategies to control
light and noise, to cluster patient care activities, and to decrease stimuli at night in order to protect
patients’ sleep cycles (1C).
7. Do not use rivastigmine to reduce the duration of delirium in ICU patients (1C).
8. Suggest withholding antipsychotics in patients with baseline QT prolongation, a history of Torsades de
Pointes, or in those receiving concomitant medications known to prolong the QT interval (2C).
9. When sedation is required in delirious ICU patients, suggest using dexmedetomidine rather than
benzodiazepine infusions for sedation in these patients, unless delirium is related to either alcohol or
benzodiazepine withdrawal
Pocket card summarizing specific pain, agitation, and delirium (PAD) guideline statements and recommendations (back side). BPS = Behavioral Pain Scale; CPOT
= Critical-Care Pain Observation
Tool; RASS = Richmond Agitation and Sedation Scale; SAS = Sedation-Agitation Scale; EEG = electroencephalography; CAM-ICU = Confusion Assessment Method
for the ICU; ICDSC = ICU Delirium
Screening Checklist; ETOH = ethanol; LOS = length of stay; HTN = hypertension.
Barr J, Gilles, LF, Puntillo K, et al. Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit. Crit
Care Med. 2013;41:263-306

Withdrawal of Life-Sustaining Measures
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Most patients who die in ICU and acute-care settings do so after a decision to limit lifesustaining treatments. Physicians have an important responsibility to improve the process by
which life-sustaining treatments are withheld or withdrawn. Although little empiric evidence is
available to guide clinicians in the practical aspects of withdrawing life-sustaining treatments,
ICU physicians should thoroughly understand the goals of withdrawing life-sustaining treatments
(to remove all treatments no longer desired or indicated while ensuring patient comfort during
the process) and should develop expertise in withdrawing life-sustaining treatments in order to
minimize patient symptoms and support the family.
Withdrawal of life-sustaining treatments is a clinical procedure; physicians must have the same
preparation and expectation of its quality as for other procedures. The rationale for the decision
to withdraw life support should be documented in the medical record. Several topics should be
discussed with families, including explaining how interventions will be withdrawn, how the
patient’s comfort will be ensured, the patient’s expected length of survival, and family or patient
preferences about other aspects of end-of-life care. An explicit plan for performing the procedure
and handling complications should be formulated. The patient should be in the appropriate
setting with irrelevant monitoring removed; the process should be carefully documented,
including reasons for increasing sedation or analgesia; and outcomes should be evaluated to
improve the quality of future care.
Once a decision is made and a time is set to withdraw life-sustaining treatments, the course and
timing of withdrawal should be determined by the potential for patient discomfort as treatment is
stopped. Although time should be provided for family to say goodbye, the only rationale for
tapering life-sustaining treatment is to allow time to meet the patient’s needs for symptom
control. Vasopressors, antibiotics, nutrition, or most other critical care treatments can be
discontinued immediately, without tapering. Mechanical ventilation is one of the few life-support
treatments for which abrupt termination can lead to discomfort; consequently, physicians have a
responsibility to develop an approach to terminal ventilator discontinuation that ensures patient
comfort. A protocol that explicitly details an approach to withdrawal of life support in the ICU,
including mechanical ventilation, has been associated with high ratings of clinician satisfaction
and may help improve the quality of care, especially in settings where physicians are not familiar
with withdrawal of life support or where there is significant practice variation. A sample protocol
devised for withdrawal of mechanical ventilation is shown in Table 1. Physicians also should
inform families that, while death is expected after withdrawal of support, it may not be certain
and the timing can vary.
Any protocol for withholding life-sustaining treatments should include an explicit protocol for
sedation and analgesia during this procedure. Such a protocol, carefully developed and
implemented, has been associated with high levels of physician and nurse satisfaction, as well as
with increased use of opiates and benzodiazepines for some patients without change in time from
ventilator withdrawal to death. Furthermore, higher
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doses of opiates and benzodiazepines in the context of withdrawing mechanical ventilation has
been shown to be associated with no change or an actual increase in time from withdrawal of
mechanical ventilation to death, suggesting that these drugs can be used to provide for patient
comfort without hastening death.
Table 1
Sample Protocol for Terminal Withdrawal of Mechanical Ventilation Previously Developed and
Evaluated
*

1. Initial ventilator setting: IMV rate __, PS level __, (choose IMV or PS, not both), Fio __,
PEEP __
2. Reduce apnea, heater, and other ventilator alarms to minimum setting
3. Reduce Fio to room air and PEEP to zero over < 5 min and titrate sedation as indicated for
discomfort
4. As indicated by level of comfort, wean IMV to 4 or PS to 5 over 5 to 20 min; titrate sedation
for comfort
5. When patient is comfortable on IMV rate 4 or PS of 5, select one of the following:
Extubate patient to air
T-piece with air (not CPAP on ventilator)
2

2

•

IMV = intermittent mandatory ventilation; PS = pressure support; Fio = fraction of
inspired oxygen; PEEP = positive end-expiratory pressure; CPAP =continuous positive
airway pressure.
2
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PCN Communication 1
5 Key Elements of Patient-Centered Communication (Gustin)
Assess Patient Perspective ------------------------------------------------- Manage Uncertainty
I
I
I
Shared Decision-Making
I
I
I
Exchange Information ------------------------------------------------------ Attend To Emotion

Mnemonics:
SPIKES
S:
P:
I:
K:
E:
S:

Setting up interview
assessing patient Perception/Perspective
obtaining patient Invitation
giving Knowledge and information
addressing patient Emotions
Strategies and Summary

V:
A:
L:
U:
E:

Value patient/family input
Acknowledge emotion
Listen
Understand patient as a person
Elicit concerns

N:
U:
R:
S:
E:

Name
Understand
Respect
Support
Explore

VALUE

NURSE

ASCEND
A:
S:
C:
E:
N:
D:

Anticipate – preplanning
Summarize patient/family understanding
Acknowledge Concerns
Explore and Explain
Next steps
Document
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PCN Spiritual Assessment/Management
Spirituality (meaning, hope, relationships, forgiveness)
Existential (how and whether life has meaning and why we exist)
Palliative Care Practitioner Role in Spiritual Healing
Be:
Human
Real
Honest
Be:
Present
Listen
Be:
Sensitive to spiritual needs
Respect:
Belief systems
Include:
In intervention plan
Simple Questions:
Do you have any spiritual or religious concerns at this point?
Are there spiritual resources that could help you at this point
On-line resource:

George Washington Institute for Spirituality and Health (GWish)
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PCN Capacity Evaluation
Criterion:
Patient Ability:
Assessment Approach:
Sample Questions:

Comment:
Criterion:
Patient Ability:
Assessment Approach:

Understanding
grasp fundamental meaning of information communicated
encourage paraphrasing of disclosed information regarding condition and treatment
“please tell me in your own words…”:
“the problem with your health now”
“the recommended treatment”
“the possible risks and benefits of the treatment”
“any alternative treatments and their risks/benefits”
“risks and benefits of no treatment”
information to be understood includes nature of condition, nature and purpose of
proposed treatment, possible risks and benefits of that treatment, and alternative
approaches – including no treatment

Appreciation
acknowledge medical condition and likely consequences of treatment options
ask for description of perspective on medical condition, proposed treatment,
likely outcomes

Sample Questions:

“what do you believe is wrong with your health now?”
“do you believe that you need some kind of treatment?”
“what is treatment likely to do for you?”
“what makes you believe it will have that effect?”
“what do you believe will happen if you are not treated?”
“why do you think (this treatment) has been recommended?”

Comment:

consider that patients who do not recognize their illnesses (“lack of insight”)
cannot make valid decisions about treatment; delusions or pathologic levels of
distortion or denial are the most common causes of impairment in this criterion

Criterion:
Patient Ability:
Assessment Approach:
Sample Questions:
Comment:
Criterion:
Patient Ability:
Assessment Approach:
Sample Questions:
Comment:

Deliberation/Reasoning
demonstrate rational process of manipulating the relevant information
ask for comparison of treatment options/consequences and reasons for choice
“how did you decide to accept or reject the recommended treatment?”
“what makes (chosen option) better than (alternative option) for you?”
focus on process of decision-making, not outcome; patients have right to make
“unreasonable” choices

Communication
clearly indicate a treatment choice
ask patient to identify/indicate a treatment choice
“have you decided to follow a recommendation for treatment?”
“can you tell me what that decision is?”
OR “what is making it hard for you to decide”
frequent reversals of choice because of psych/neuro conditions may indicate
lack of capacity”

Pediatric End-of-Life (EOL) Summary/Overview
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Pathways to EOL
Non-Escalation of Life Prolonging Therapies
Mode of Death:
Progression of Underlying Disease
Comments:
Difficult to control or predict exactly when and how death will occur
Allow family to recognize dying as a consequence of disease progression and beyond their
control
Blood transfusions and antibiotics may provide comfort and should be judged on the basis of
their
actual effects on comfort (e.g. fluid overload versus improved energy level)
Compassionate Extubation
Mode of Death:
Hypoxia, hypercarbia, acidosis, hemodynamic collapse
Comments:
Allows for a rapid death if lung disease is severe or if patient has no respiratory drive
Prepare for possible secretions, anxiety, dyspnea
Stop neuromuscular blockade prior to extubation
Consider pre-medication to help alleviate symptoms
Cessation of Hemodynamic Support (Inotropes, Vasopressors, ECMO)
Mode of Death: Hypotension progressing to acidosis, shock, coma
Comments:
Hypotension can result in significant sedation
Death may be rapid if patient is on significant hemodynamic support or may be hours to days if
on
lesser degrees of hemodynamic support
Can precipitate symptoms of heart failure or ischemia
Discontinuation of Dialysis
Mode of Death: Acidosis, Electrolyte Disturbances, Uremia, Fluid Overload,
Comments
Uremia can cause sedation
Symptoms of fluid overload be distressing-prepare family and treat symptoms appropriately
Typically a prolonged course (days to weeks)
However, death can ultimately be rapid (hyperkalemia with cardiac arrest)
Withholding of Artificial Nutrition or Fluid
Mode of Death: Dehydration and Underlying Condition (NOT Starvation)
Comments:
Aids with comfort related to fluid status and digestive system shutting down
Hunger and thirst lessen after 1-2 days with an increase in ketones and release of endogenous
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endorphins which can have an analgesic effect
Death tends to occur within days to weeks (reported range 2-37 days) and often during sleep
Requires good mouth care
Dramatic physical changes can occur: significant weight loss, skin changes, sunken eyes,
concave abdomen, abnormal respiration (including prolonged apnea)
Emotionally charged topic: important to have a consensus among team to provide a united
front
Provide emotional support to family around concern for “starving” or “killing” their child, legal
ramifications of decisions, judgment of extended family and friends
Avoid use of terms “withdrawal of care” and “reduction of care”; instead use terms such as
“focus on comfort and quality of life” or “preventing suffering”
Care itself is never withdrawn, goals for care have changed while care often intensifies in other
ways
Difficult care choices are ideally made when there is consensus among patients, parents,
providers
However, in some cases it can be important to emphasize that decisions are provider-directed
to minimize parental feelings of burden and guilt
Limit invasive tests or monitoring that do not promote comfort
Some parents want to know how long their child will live
Guide parents by speaking in terms of minutes/hours, hours/days, days/weeks,
weeks/months
Acknowledge that it is difficult to predict length of survival-Examples:
“It is hard for us to know and we find that when we make predictions we are frequently
Wrong. Based on _____’s medical situation, my best estimate would be ______. It is
important to know, however that children often surprise us and may live longer or
shorter than we anticipate, so it is important that we are prepared for both situations”
“Based on how much support ______is currently receiving, we expect he/she will die
within _________ Some kids do surprise us, though, and it is possible that he/she could
live for a longer time. Regardless of what happens, we are ready to keep ________
comfortable.”

Guidelines for Pediatric EOL Symptom Management
Dyspnea
Pharmacologic
Opioids are the primary treatment for dyspnea at EOL
Opioid dose generally 25% of the amount used for pain
Consider lorazepam as an adjunct
Non-Pharmacologic
Oxygen
Elevate head of bed
Bedside fan
Fluid restriction
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Secretions
Pharmacologic
Glycopyrrolate
Non-Pharmacologic
Fluid restriction
Gentle suction
Reposition
Educate families that noisy breathing may occur when death is imminent
May be distressing to hear but the child likely does not experience
discomfort
Agitation/Anxiety
Pharmacologic
Lorazepam
Consider midazolam infusion (if lorazepam required more than q 3 hours)
Note agitation caused by delirium may be worsened by benzodiazepine
Consider use of anti-psychotic
Non-Pharmacologic
Low lighting
Soothing music
Familiar people/objects
Decrease sensory stimuli
Provide developmentally appropriate supportive therapy
Nausea/Vomiting
Pharmacologic
1st line: ondansetron or granisetron
2nd line: lorazepam
3rd line: prochlorperazine, haloperidol, metoclopramide, dexamethasone
Non-Pharmacologic
Avoid irritating foods and smells
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Consider etiology/source of nausea when selecting agent
Be aware of distinction between true reduction in nausea versus sedation
Pain

Pharmacologic
Opioid with appropriate loading dose
Reassess patient frequently
Consider repeat doses q 20 min x 3 doses
After 3 doses consider continuous infusion
Once pain is adequately controlled with intermittent dosing
Consider switching to continuous infusion
Determine 24 hour opioid use (OME)
Consider starting with 50% OME, calculate hourly rate
For patients already on a continuous infusion with symptom escalation
Adjust rate no more often than every 8 hours
Add total prn boluses
Divide by the number of hours over which those boluses were
given
Divide again by 2 (50% reduction)
Add to current basal rate, adjust prn dosing based on new hourly
Rate

General Considerations:
No ceiling dose for opioids in EOL symptom management
Dosing interval for intermittent dosing may need to be shortened to achieve comfort
Take into account other possible sedating medications
Consider long-acting opioids that may not yet have achieved steady state (e.g. methadone,
fentanyl TD)
Consider expected course/nature of pain, anticipated procedure etc.
Consider adjunctive medications and non-pharmacologic interventions
Consider opioid rotation if significant adverse effects
Non-Pharmacologic
See measures for agitation/anxiety
Consider other integrative therapies
Acupuncture, biofeedback, guided imagery, mindfulness,
Meditation, aromatherapy
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Phases of Death
Pre-Active
Withdrawal from active participation in social activities
Increased and prolonged periods of sleep
Hypersensitivity to stimulation (e.g. light, sound, touch)
Decreased appetite and PO intake
Increased restlessness, confusion, agitation
Active
Circulation
Blood pressure goes down, heart rate faster, pulse weaker
Cold extremities, profound mottling of skin, cyanosis
Fluids and metabolism
Inability to tolerate enteral nutrition
Decreased energy requirements
Notable decrease in urine and stool output, bowel or bladder
incontinence
Respiratory
Changes in breathing pattern
Cheyne-Stokes breathing
Agonal breathing
Prolonged periods of apnea
Inability to close mouth or constant breathing through mouth
Difficulty managing secretions, gurgling/noisy breathing (“death rattle”)
Neurologic
Unresponsive or responsive only to significant stimulation
Limited purposeful movement
Decreased muscle tone
May experience a sudden unexplained surge of energy
“Terminal Agitation” severe multifactorial distress
Rule out other confounding variable:
Urinary retention, Constipation, Medication toxicity
Unable to speak despite appearing awake
Senses
Hearing may remain intact until death
Be cognizant of what is said around patient
Vision is blurred

Confusion Assessment Method for the ICU-7 Delirium Severity Scale
1. Acute onset or fluctuation of mental status:
Is the patient different than his/her baseline mental status?
Has the patient had any fluctuation in mental status in the last 24
hours as evidenced by fluctuation on a sedation/level of
consciousness scale (such as RASS or GCS)?
2. Inattention
Say to the patient, “I am going to read you a series of 10 letters.
Whenever you hear the letter “A”, indicate by squeezing my hand.”
Read letters from the following letter list in a normal tone 3 seconds
apart. “SAVEAHAART” (Errors are counted when patient fails to
squeeze on the letter “A” or when the patient squeezes on any
letter other than “A.”)
3. Altered Level of Consciousness
Present if the actual Richmond Agitation-Sedation Scale
Score is anything other than alert and calm (zero)

4. Disorganized Thinking
Yes/No questions:
Will a stone float on water?
Are there fish in the sea?
Does one pound weigh more than two pounds?
Can you use a hammer to pound a nail?
Errors are counted when the patient incorrectly answers a question.
Command: Say to patient “Hold up this many fingers” (Hold two
Fingers in front of patient). “Now do the same with the other hand”
(Do not repeat number of fingers)
An error is counted if patient is unable to complete entire command
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0 for absent
1 for present

0 for absent
(correct 8 or more)
1 for inattention
(correct 4-7)
2 for severe inattention
(correct 0-3)
0 for absent
(RASS:0)
1 for altered level
(RASS:1, -1)
2 for severe altered
(RASS:>1, <-1)
0 for absent
(correct 4 or more)
1 for disorganized
(correct 2-3)
2 for severe
(correct 0-1)
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